

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 9/28 // C11D 3/386</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 96/23873</b> <b>(43) International Publication Date:</b> 8 August 1996 (08.08.96)
<b>(21) International Application Number:</b> PCT/DK96/00056 <b>(22) International Filing Date:</b> 5 February 1996 (05.02.96)  <b>(30) Priority Data:</b> 0126/95 3 February 1995 (03.02.95) DK 0336/95 29 March 1995 (29.03.95) DK 1097/95 29 September 1995 (29.09.95) DK 1121/95 6 October 1995 (06.10.95) DK  <b>(71) Applicant (for all designated States except US):</b> NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsvaerd (DK).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> BISGÅRD-FRANTZEN, Henrik [DK/DK]; Novo Nordisk A/S, Novo Allé, DK-2880 Bagsvaerd (DK). SVENDSEN, Allan [DK/DK]; Novo Nordisk A/S, Novo Allé, DK-2880 Bagsvaerd (DK). BORCHERT, Torben, Vedel [DK/DK]; Novo Nordisk A/S, Novo Allé, DK-2880 Bagsvaerd (DK).  <b>(74) Common Representative:</b> NOVO NORDISK A/S; Corporate Patents, Novo Allé, DK-2880 Bagsvaerd (DK).	<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AZ, BY, KG, KZ, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
<b>(54) Title:</b> AMYLASE VARIANTS  <b>(57) Abstract</b>  A variant of a parent $\alpha$ -amylase, which parent $\alpha$ -amylase (i) has an amino acid sequence selected from the amino acid sequences shown in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, and SEQ ID No. 7, respectively; or (ii) displays at least 80 % homology with one or more of these amino acid sequences; and/or displays immunological cross-reactivity with an antibody raised against a $\alpha$ -amylase having one of these amino acid sequences; and/or is encoded by a DNA sequence which hybridizes with the same probe as a DNA sequence encoding a $\alpha$ -amylase having one of these amino acid sequences; in which variant: (a) at least one amino acid residue of the parent $\alpha$ -amylase has been deleted; and/or (b) at least one amino acid residue of the parent $\alpha$ -amylase has been replaced by a different amino acid residue; and/or (c) at least one amino acid residue has been inserted relative to the parent $\alpha$ -amylase; the variant having $\alpha$ -amylase activity and exhibiting at least one of the following properties relative to the parent $\alpha$ -amylase: increased thermostability; increased stability towards oxidation; and reduced $\text{Ca}^{2+}$ dependency; with the proviso that the amino acid sequence of the variant is not identical to any of the amino acid sequences shown in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 and SEQ ID No. 7, respectively.		

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

## AMYLASE VARIANTS

### FIELD OF THE INVENTION

The present invention relates to  $\alpha$ -amylase variants having improved properties relative to the parent enzyme (e.g. improved thermal and/or oxidation stability  
5 and/or reduced calcium ion dependency), and thereby improved washing and/or dishwashing (and/or textile desizing) performance. The invention also relates to DNA constructs encoding the variants, and to vectors and cells harbouring the DNA constructs. The invention further relates to methods of producing the amylase variants, and to detergent additives and detergent compositions comprising the  
10 amylase variants. Furthermore, the invention relates to the use of the amylase variants for textile desizing.

### BACKGROUND OF THE INVENTION

$\alpha$ -Amylase enzymes have been used industrially for a number of years and for a variety of different purposes, the most important of which are starch liquefaction,  
15 textile desizing, starch modification in the paper and pulp industry, and for brewing and baking. A further use of  $\alpha$ -amylases which is becoming increasingly important is the removal of starchy stains during washing or dishwashing.

In recent years attempts have been made to construct  $\alpha$ -amylase variants having improved properties with respect to specific uses such as starch liquefaction and  
20 textile desizing.

For instance, US 5,093,257 discloses chimeric  $\alpha$ -amylases comprising an N-terminal part of a *B. stearothermophilus*  $\alpha$ -amylase and a C-terminal part of a *B. licheniformis*  $\alpha$ -amylase. The chimeric  $\alpha$ -amylases are stated to have unique properties, such as a different thermostability, as compared to their parent  
25  $\alpha$ -amylase. However, all of the specifically described chimeric  $\alpha$ -amylases were

shown to have a decreased enzymatic activity as compared to their parent  $\alpha$ -amylases.

EP 252 666 describes hybrid amylases of the general formula Q-R-L, in which Q is a N-terminal polypeptide residue of from 55 to 60 amino acid residues which is at least 75% homologous to the 57 N-terminal amino acid residues of a specified  $\alpha$ -amylase from *B. amyloliquefaciens*, R is a specified polypeptide, and L is a C-terminal polypeptide comprising from 390 to 400 amino acid residues which is at least 75% homologous to the 395 C-terminal amino acid residues of a specified *B. licheniformis*  $\alpha$ -amylase.

10 Suzuki et al. (1989) disclose chimeric  $\alpha$ -amylases, in which specified regions of a *B. amyloliquefaciens*  $\alpha$ -amylase have been substituted for the corresponding regions of a *B. licheniformis*  $\alpha$ -amylase. The chimeric  $\alpha$ -amylases were constructed with the purpose of identifying regions responsible for thermostability. Such regions were found to include amino acid residues 177-186 and amino acid residues 255-  
15 270 of the *B. amyloliquefaciens*  $\alpha$ -amylase. The alterations of amino acid residues in the chimeric  $\alpha$ -amylases did not seem to affect properties of the enzymes other than their thermostability.

WO 91/00353 discloses  $\alpha$ -amylase mutants which differ from their parent  $\alpha$ -amylase in at least one amino acid residue. The  $\alpha$ -amylase mutants disclosed in said patent  
20 application are stated to exhibit improved properties for application in the degradation of starch and/or textile desizing due to their amino acid substitutions. Some of the mutants exhibit improved stability, but no improvements in enzymatic activity were reported or indicated. The only mutants exemplified are prepared from a parent *B. licheniformis*  $\alpha$ -amylase and carry one of the following mutations: H133Y  
25 or H133Y + T149I. Another suggested mutation is A111T.

FR 2,676,456 discloses mutants of the *B. licheniformis*  $\alpha$ -amylase, in which an amino acid residue in the proximity of His 133 and/or an amino acid residue in the proximity of Ala 209 have been replaced by a more hydrophobic amino acid resi-



due. The resulting  $\alpha$ -amylase mutants are stated to have an improved thermostability and to be useful in the textile, paper, brewing and starch liquefaction industry.

EP 285 123 discloses a method of performing random mutagenesis of a nucleotide  
5 sequence. As an example of such sequence a nucleotide sequence encoding a *B. stearotherophilus*  $\alpha$ -amylase is mentioned. When mutated, an  $\alpha$ -amylase variant having improved activity at low pH values is obtained.

In none of the above references is it mentioned or even suggested that  $\alpha$ -amylase mutants may be constructed which have improved properties with respect to the  
10 detergent industry.

EP 525 610 relates to mutant enzymes having improved stability towards ionic tensides (surfactants). The mutant enzymes have been produced by replacing an amino acid residue in the surface part of the parent enzyme with another amino acid residue. The only mutant enzyme specifically described in EP 525 610 is a  
15 protease. Amylase is mentioned as an example of an enzyme which may obtain an improved stability towards ionic tensides, but the type of amylase, its origin or specific mutations are not specified.

WO 94/02597 discloses  $\alpha$ -amylase mutants which exhibit improved stability and activity in the presence of oxidizing agents. In the mutant  $\alpha$ -amylases, one or more  
20 methionine residues have been replaced with amino acid residues different from Cys and Met. The  $\alpha$ -amylase mutants are stated to be useful as detergent and/or dishwashing additives as well as for textile desizing.

WO 94/18314 discloses oxidatively stable  $\alpha$ -amylase mutants, including mutations in the M197 position of *B. licheniformis*  $\alpha$ -amylase.

25 EP 368 341 describes the use of pullulanase and other amylolytic enzymes optionally in combination with an  $\alpha$ -amylase for washing and dishwashing.

An object of the present invention is to provide  $\alpha$ -amylase variants which - relative to their parent  $\alpha$ -amylase - possess improved properties of importance, *inter alia*, in relation to the washing and/or dishwashing performance of the variants in question, e.g. increased thermal stability, increased stability towards oxidation, 5 reduced dependency on  $\text{Ca}^{2+}$  ion and/or improved stability or activity in the pH region of relevance in, e.g., laundry washing or dishwashing. Such variant  $\alpha$ -amylases have the advantage, among others, that they may be employed in a lower dosage than their parent  $\alpha$ -amylase. Furthermore, the  $\alpha$ -amylase variants may be able to remove starchy stains which cannot, or can only with difficulty, be removed 10 by  $\alpha$ -amylase detergent enzymes known today.

#### BRIEF DISCLOSURE OF THE INVENTION

A goal of the work underlying the present invention was to improve, if possible, the stability of, *inter alia*, particular  $\alpha$ -amylases which are obtainable from *Bacillus* strains and which themselves had been selected on the basis of their starch 15 removal performance in alkaline media (such as in detergent solutions as typically employed in laundry washing or dishwashing) relative to many of the currently commercially available  $\alpha$ -amylases. In this connection, the present inventors have surprisingly found that it is in fact possible to improve properties of the types mentioned earlier (*vide supra*) of such a parent  $\alpha$ -amylase by judicial modification 20 of one or more amino acid residues in various regions of the amino acid sequence of the parent  $\alpha$ -amylase. The present invention is based on this finding.

Accordingly, in a first aspect the present invention relates to variants of a parent  $\alpha$ -amylase, the parent  $\alpha$ -amylase in question being one which:

i) has one of the amino acid sequences shown in SEQ ID No. 1, SEQ ID No. 2, 25 SEQ ID No. 3 and SEQ ID No. 7, respectively, herein; or

ii) displays at least 80% homology with one or more of the amino acid sequences shown in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 and SEQ ID No. 7; and/or

displays immunological cross-reactivity with an antibody raised against an  $\alpha$ -amylase having one of the amino acid sequences shown in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 and SEQ ID No. 7, respectively; and/or is encoded by a DNA sequence which hybridizes with the same probe as a DNA sequence encoding  
5 an  $\alpha$ -amylase having one of the amino acid sequences shown in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 and SEQ ID No. 7, respectively.

An  $\alpha$ -amylase variant of the invention is subject to the proviso that it is a variant which does not have an amino acid sequence identical to the amino acid sequence shown in SEQ ID No. 1, in SEQ ID No. 2, in SEQ ID No. 3 or in SEQ ID No. 7.

10 DNA sequences encoding the first three of the  $\alpha$ -amylase amino acid sequences in question are shown in SEQ ID No. 4 (encoding the amino acid sequence shown in SEQ ID No. 1), SEQ ID No. 5 (encoding the amino acid sequence shown in SEQ ID No. 2) and SEQ ID No. 6 (encoding the amino acid sequence shown in SEQ ID No. 3).

15 The amino acid sequences of the SEQ ID No. 1 and SEQ ID No. 2 parent  $\alpha$ -amylases, and the corresponding DNA sequences (SEQ ID No. 4 and SEQ ID No. 5, respectively) are also disclosed in WO 95/26397 (under the same SEQ ID Nos. as in the present application).

The variants of the invention are variants in which: (a) at least one amino acid  
20 residue of the parent  $\alpha$ -amylase has been deleted; and/or (b) at least one amino acid residue of the parent  $\alpha$ -amylase has been replaced (i.e. substituted) by a different amino acid residue; and/or (c) at least one amino acid residue has been inserted relative to the parent  $\alpha$ -amylase. The variants in question have themselves  $\alpha$ -amylase activity and exhibit at least one of the following properties relative to the  
25 parent  $\alpha$ -amylase:

increased thermostability, i.e. satisfactory retention of enzymatic activity at a temperature higher than that suitable for use with the parent enzyme;

increased oxidation stability, i.e. increased resistance to degradation by oxidants (such as oxygen, oxidizing bleaching agents and the like);

reduced  $\text{Ca}^{2+}$  dependency, i.e. the ability to function satisfactorily in the presence of a lower  $\text{Ca}^{2+}$  concentration than in the case of the parent  $\alpha$ -amylase.  $\alpha$ -Amylases  
5 with such reduced  $\text{Ca}^{2+}$  dependency are highly desirable for use in detergent compositions, since such compositions typically contain relatively large amounts of substances (such as phosphates, EDTA and the like) which bind calcium ions strongly.

Examples of other desirable improvements or modifications of properties (relative  
10 to the parent  $\alpha$ -amylase in question) which may be achieved with a variant according to the invention are:

increased stability and/or  $\alpha$ -amylolytic activity at neutral to relatively high pH values, e.g. at pH values in the range of 7-10.5, such as in the range of 8.5-10.5;

increased  $\alpha$ -amylolytic activity at relatively high temperatures, e.g. temperatures in  
15 the range of 40-70°C;

increase or decrease of the isoelectric point (pI) so as to better match the pI value for the  $\alpha$ -amylase variant in question to the pH of the medium (e.g. a laundry washing medium, dishwashing medium or textile-desizing medium) in which the variant is to be employed (*vide infra*); and

20 improved binding of a particular type of substrate, improved specificity towards a substrate, and/or improved specificity with respect to cleavage (hydrolysis) of substrate.

An amino acid sequence is considered to be X% homologous to the parent  $\alpha$ -amylase if a comparison of the respective amino acid sequences, performed via  
25 known algorithms, such as the one described by Lipman and Pearson in Science

227 (1985) p. 1435, reveals an identity of X%. The GAP computer program from the GCG package, version 7.3 (June 1993), may suitably be used, employing default values for GAP penalties [Genetic Computer Group (1991) Programme Manual for the GCG Package, version 7, 575 Science Drive, Madison, Wisconsin, USA 53711].

5 In the context of the present invention, "improved performance" as used in connection with washing and dishwashing is, as already indicated above, intended to mean improved removal of starchy stains, i.e. stains containing starch, during washing or dishwashing, respectively. The performance may be determined in conventional washing and dishwashing experiments and the improvement evaluated  
10 as a comparison with the performance of the parent  $\alpha$ -amylase in question. An example of a small-scale "mini dishwashing test" which can be used as an indicator of dishwashing performance is described in the Experimental section, below.

It will be understood that a variety of different characteristics of an  $\alpha$ -amylase variant, including specific activity, substrate specificity,  $K_m$  (the so-called "Michaelis  
15 constant" in the Michaelis-Menten equation),  $V_{max}$  [the maximum rate (plateau value) of conversion of a given substrate determined on the basis of the Michaelis-Menten equation], pI, pH optimum, temperature optimum, thermoactivation, stability towards oxidants or surfactants (e.g. in detergents), etc., taken alone or in combination, can contribute to improved performance. The skilled person will be aware that the  
20 performance of the variant cannot, alone, be predicted on the basis of the above characteristics, but would have to be accompanied by washing and/or dishwashing performance tests.

In further aspects the invention relates to a DNA construct comprising a DNA sequence encoding an  $\alpha$ -amylase variant of the invention, a recombinant expression  
25 vector carrying the DNA construct, a cell which is transformed with the DNA construct or the vector, as well as a method of producing an  $\alpha$ -amylase variant by culturing such a cell under conditions conducive to the production of the  $\alpha$ -amylase variant, after which the  $\alpha$ -amylase variant is recovered from the culture.

In a further aspect the invention relates to a method of preparing a variant of a parent  $\alpha$ -amylase which by virtue of its improved properties as described above exhibits improved washing and/or dishwashing performance as compared to the parent  $\alpha$ -amylase. This method comprises

- 5 a) constructing a population of cells containing genes encoding variants of said parent  $\alpha$ -amylase,
  - b) screening the population of cells for  $\alpha$ -amylase activity under conditions simulating at least one washing and/or dishwashing condition,
  - c) isolating a cell from the population containing a gene encoding a variant of said
  - 10 parent  $\alpha$ -amylase which has improved activity as compared with the parent  $\alpha$ -amylase under the conditions selected in step b),
  - d) culturing the cell isolated in step c) under suitable conditions in an appropriate culture medium, and
  - e) recovering the  $\alpha$ -amylase variant from the culture obtained in step d).
- 15 The invention also relates to a variant (which is a variant according the invention) prepared by the latter method.

In the present context, the term "simulating at least one washing and/or dishwashing condition" is intended to indicate a simulation of, e.g., the temperature or pH prevailing during washing or dishwashing, or of the chemical composition of

20 a detergent composition to be used in the washing or dishwashing treatment. The term "chemical composition" is intended to include one, or a combination of two or more, constituents of the detergent composition in question. The constituents of a number of different detergent compositions are listed further below.

The "population of cells" referred to in step a) may suitably be constructed by

25 cloning a DNA sequence encoding a parent  $\alpha$ -amylase and subjecting the DNA to site-directed or random mutagenesis as described herein.

In the present context the term "variant" is used interchangeably with the term "mutant". The term "variant" is intended to include hybrid  $\alpha$ -amylases, i.e.  $\alpha$ -amylases comprising parts of at least two different  $\alpha$ -amylolytic enzymes. Thus, such a hybrid may be constructed, e.g., from: one or more parts each deriving from  
5 a variant as already defined above; or one or more parts each deriving from a variant as already defined above, and one or more parts each deriving from an unmodified parent  $\alpha$ -amylase. In this connection, the invention also relates to a method of producing such a hybrid  $\alpha$ -amylase having improved washing and/or dishwashing performance as compared to any of its constituent enzymes (i.e. as  
10 compared to any of the enzymes which contribute a part to the hybrid), which method comprises:

- a) recombining *in vivo* or *in vitro* the N-terminal coding region of an  $\alpha$ -amylase gene or corresponding cDNA of one of the constituent  $\alpha$ -amylases with the C-terminal coding region of an  $\alpha$ -amylase gene or corresponding cDNA of another constituent  
15  $\alpha$ -amylase to form recombinants,
- b) selecting recombinants that produce a hybrid  $\alpha$ -amylase having improved washing and/or dishwashing performance as compared to any of its constituent  $\alpha$ -amylases,
- c) culturing recombinants selected in step b) under suitable conditions in an  
20 appropriate culture medium, and
- d) recovering the hybrid  $\alpha$ -amylase from the culture obtained in step c).

In further aspects the invention relates to the use of an  $\alpha$ -amylase variant of the invention [including any variant or hybrid prepared by one of the above mentioned methods] as a detergent enzyme, in particular for washing or dishwashing, to a  
25 detergent additive and a detergent composition comprising the  $\alpha$ -amylase variant, and to the use of an  $\alpha$ -amylase variant of the invention for textile desizing.

Random mutagenesis may be used to generate variants according to the invention, and the invention further relates to a method of preparing a variant of a parent  $\alpha$ -amylase, which method comprises

(a) subjecting a DNA sequence encoding the parent  $\alpha$ -amylase to random mutagenesis,

(b) expressing the mutated DNA sequence obtained in step (a) in a host cell, and

(c) screening for host cells expressing a mutated amylolytic enzyme which has improved properties as described above (e.g. properties such as decreased calcium dependency, increased oxidation stability, increased thermostability, and/or improved activity at relatively high pH) as compared to the parent  $\alpha$ -amylase.

## DETAILED DISCLOSURE OF THE INVENTION

### Nomenclature

10 In the present description and claims, the conventional one-letter codes for nucleotides and the conventional one-letter and three-letter codes for amino acid residues are used. For ease of reference,  $\alpha$ -amylase variants of the invention are described by use of the following nomenclature:

Original amino acid(s):position(s):substituted amino acid(s)

15

According to this nomenclature, and by way of example, the substitution of alanine for asparagine in position 30 is shown as:

Ala 30 Asn                      or                      A30N

a deletion of alanine in the same position is shown as:

20                      Ala 30 \*                      or                      A30\*

and insertion of an additional amino acid residue, such as lysine, is shown as:

Ala 30 AlaLys                      or                      A30AK

A deletion of a consecutive stretch of amino acid residues, exemplified by amino acid residues 30-33, is indicated as (30-33)\*.



Where a specific  $\alpha$ -amylase contains a "deletion" (i.e. lacks an amino acid residue) in comparison with other  $\alpha$ -amylases and an insertion is made in such a position, this is indicated as:

\* 36 Asp                      or                      \*36D

5 for insertion of an aspartic acid in position 36

Multiple mutations are separated by plus signs, i.e.:

Ala 30 Asp + Glu 34 Ser                      or                      A30N+E34S

representing mutations in positions 30 and 34 (in which alanine and glutamic acid replace, i.e. are substituted for, asparagine and serine, respectively).

10 When one or more alternative amino acid residues may be inserted in a given position this is indicated as:

A30N,E or  
A30N or A30E

Furthermore, when a position suitable for modification is identified herein without  
15 any specific modification being suggested, it is to be understood that any other amino acid residue may be substituted for the amino acid residue present in that position (i.e. any amino acid residue - other than that normally present in the position in question - chosen among A, R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y and V). Thus, for instance, when a modification (replacement) of a  
20 methionine in position 202 is mentioned, but not specified, it is to be understood that any of the other amino acids may be substituted for the methionine, i.e. any other amino acid chosen among A,R,N,D,C,Q,E,G,H,I,L,K,F,P,S,T,W,Y and V.

#### The parent $\alpha$ -amylase

As already indicated, an  $\alpha$ -amylase variant of the invention is very suitably prepared  
25 on the basis of a parent  $\alpha$ -amylase having one of the amino acid sequences shown in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 and SEQ ID No. 7, respectively (*vide infra*).

The parent  $\alpha$ -amylases having the amino acid sequences shown in SEQ ID No. 1 and SEQ ID No. 2, respectively, are obtainable from alkaliphilic *Bacillus* strains (strain NCIB 12512 and strain NCIB 12513, respectively), both of which are described in detail in EP 0 277 216 B1. The preparation, purification and  
5 sequencing of these two parent  $\alpha$ -amylases is described in WO 95/26397 [see the Experimental section herein (*vide infra*)].

The parent  $\alpha$ -amylase having the amino acid sequence shown in SEQ ID No. 3 is obtainable from *Bacillus stearothermophilus* and is described in, *inter alia*, J. Bacteriol. 166 (1986) pp. 635-643.

- 10 The parent  $\alpha$ -amylase having the amino acid sequence shown in SEQ ID No. 7 (which is the same sequence as that numbered 4 in Fig. 1) is obtainable from a "*Bacillus* sp. #707" and is described by Tsukamoto et al. in Biochem. Biophys. Res. Commun. 151 (1988) pp. 25-31.

Apart from variants of the above-mentioned parent  $\alpha$ -amylases having the amino  
15 acid sequences shown in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 and SEQ ID No. 7, respectively, other interesting variants according to the invention include variants of parent  $\alpha$ -amylases which have amino acid sequences exhibiting a high degree of homology, such as at least 70% homology, preferably (as already indicated) at least 80% homology, desirably at least 85% homology, and more  
20 preferably at least 90% homology, e.g.  $\geq 95\%$  homology, with at least one of the latter four amino acid sequences.

As also already indicated above, further criteria for identifying a suitable parent  $\alpha$ -amylase are a) that the  $\alpha$ -amylase displays an immunological cross-reaction with an antibody raised against an  $\alpha$ -amylase having one of the amino acid sequences  
25 shown in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 and SEQ ID No. 7, respectively, and/or b) that the  $\alpha$ -amylase is encoded by a DNA sequence which hybridizes with the same probe as a DNA sequence encoding an  $\alpha$ -amylase having

one of the amino acid sequences shown in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 and SEQ ID No. 7, respectively.

As already mentioned, with regard to determination of the degree of homology of polypeptides (such as enzymes), amino acid sequence comparisons can be performed using known algorithms, such as the one described by Lipman and Pearson (1985).

Assays for immunological cross-reactivity may be carried out using an antibody raised against, or reactive with, at least one epitope of the  $\alpha$ -amylase having the amino acid sequence shown in SEQ ID No. 1, or of the  $\alpha$ -amylase having the amino acid sequence shown in SEQ ID No. 2, or of the  $\alpha$ -amylase having the amino acid sequence shown in SEQ ID No. 3, or of the  $\alpha$ -amylase having the amino acid sequence shown in SEQ ID No. 7.

The antibody, which may either be monoclonal or polyclonal, may be produced by methods known in the art, e.g. as described by Hudson et al. (1989). Examples of suitable assay techniques well known in the art include Western Blotting and Radial Immunodiffusion Assay, e.g. as described by Hudson et al. (1989).

The oligonucleotide probe for use in the identification of suitable parent  $\alpha$ -amylases on the basis of probe hybridization [criterion b) above] may, by way of example, suitably be prepared on the basis of the full or partial amino acid sequence of an  $\alpha$ -amylase having one of the sequences shown in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 and SEQ ID No. 7, respectively, or on the basis of the full or partial nucleotide sequence corresponding thereto.

Suitable conditions for testing hybridization involve presoaking in 5xSSC and prehybridizing for 1h at ~40°C in a solution of 20% formamide, 5xDenhardt's solution, 50mM sodium phosphate, pH 6.8, and 50 $\mu$ g of denatured sonicated calf thymus DNA, followed by hybridization in the same solution supplemented with 100 $\mu$ M ATP

for 18h at ~40°C, or using other methods described by, e.g., Sambrook et al. (1989).

Influence of mutations on particular properties

From the results obtained by the present inventors it appears that changes in a particular property, e.g. thermal stability or oxidation stability, exhibited by a variant relative to the parent  $\alpha$ -amylase in question can to a considerable extent be correlated with the type of, and positioning of, mutation(s) (amino acid substitutions, deletions or insertions) in the variant. It is to be understood, however, that the observation that a particular mutation or pattern of mutations leads to changes in a given property in no way excludes the possibility that the mutation(s) in question can also influence other properties.

Oxidation stability: With respect to increasing the oxidation stability of an  $\alpha$ -amylase variant relative to its parent  $\alpha$ -amylase, it appears to be particularly desirable that at least one, and preferably multiple, oxidizable amino acid residue(s) of the parent has/have been deleted or replaced (i.e. substituted by) a different amino acid residue which is less susceptible to oxidation than the original oxidizable amino acid residue.

Particularly relevant oxidizable amino acid residues in this connection are cysteine, methionine, tryptophan and tyrosine. Thus, for example, in the case of parent  $\alpha$ -amylases containing cysteine it is anticipated that deletion of cysteine residues, or substitution thereof by less oxidizable amino acid residues, will be of importance in obtaining variants with improved oxidation stability relative to the parent  $\alpha$ -amylase.

In the case of the above-mentioned parent  $\alpha$ -amylases having the amino acid sequences shown in SEQ ID No. 1, SEQ ID No. 2 and SEQ ID No. 7, respectively, all of which contain no cysteine residues but have a significant methionine content, the deletion or substitution of methionine residues is particularly relevant with respect to achieving improved oxidation stability of the resulting variants. Thus,

deletion or substitution [e.g. by threonine (T), or by one of the other amino acids listed above] of one or more of the methionine residues in positions M9, M10, M105, M202, M208, M261, M309, M382, M430 and M440 of the amino acid sequences shown in SEQ ID No. 1, SEQ ID No. 2 and SEQ ID No. 7, and/or in  
5 position M323 of the amino acid sequence shown in SEQ ID No. 2 (or deletion or substitution of methionine residues in equivalent positions in the sequence of another  $\alpha$ -amylase meeting one of the other criteria for a parent  $\alpha$ -amylase mentioned above) appear to be particularly effective with respect to increasing the oxidation stability.

- 10 In the case of the parent  $\alpha$ -amylase having the amino acid sequence shown in SEQ ID No. 3, relevant amino acid residues which may be deleted or substituted with a view to improving the oxidation stability include the single cysteine residue (C363) and - by analogy with the sequences shown in SEQ ID No. 1 and SEQ ID No. 3 - the methionine residues located in positions M8, M9, M96, M200, M206, M284,  
15 M307, M311, M316 and M438.

In this connection, the term "equivalent position" denotes a position which, on the basis of an alignment of the amino acid sequence of the parent  $\alpha$ -amylase in question with the "reference"  $\alpha$ -amylase amino acid sequence in question (for example the sequence shown in SEQ ID No. 1) so as to achieve juxtapositioning  
20 of amino acid residues/regions which are common to both, corresponds most closely to (e.g. is occupied by the same amino acid residue as) a particular position in the reference sequence in question.

Particularly interesting mutations in connection with modification (improvement) of the oxidation stability of the  $\alpha$ -amylases having the amino acid sequences shown  
25 in SEQ ID No. 1, SEQ ID No. 2 and SEQ ID No. 7, respectively, are one or more of the following methionine substitutions (or equivalents thereof in the amino acid sequences of other  $\alpha$ -amylases meeting the requirements of a parent  $\alpha$ -amylase in the context of the invention): M202A,R,N,D,Q,E,G,H,I,L,K,F,P,S,T,W,Y,V.

Further relevant methionine substitutions in the amino acid sequence shown in SEQ ID No. 2 are: M323A,R,N,D,Q,E,G,H,I,L,K,F,P,S,T,W,Y,V.

Particularly interesting mutations in connection with modification (improvement) of the oxidation stability of the  $\alpha$ -amylase having the amino acid sequence shown in  
5 SEQ ID No. 3 are one or more of the following methionine substitutions:

M 2 0 0 A , R , N , D , Q , E , G , H , I , L , K , F , P , S , T , W , Y , V ;  
M 3 1 1 A , R , N , D , Q , E , G , H , I , L , K , F , P , S , T , W , Y , V ;    a n d  
M316A,R,N,D,Q,E,G,H,I,L,K,F,P,S,T,W,Y,V.

Thermal stability: With respect to increasing the thermal stability of an  $\alpha$ -amylase  
10 variant relative to its parent  $\alpha$ -amylase, it appears to be particularly desirable to delete at least one, and preferably two or even three, of the following amino acid residues in the amino acid sequence shown in SEQ ID No. 1 (or their equivalents): F180, R181, G182, T183, G184 and K185. The corresponding, particularly relevant (and equivalent) amino acid residues in the amino acid sequences shown in SEQ  
15 ID No. 2, SEQ ID No. 3 and SEQ ID No. 7, respectively, are: F180, R181, G182, D183, G184 and K185 (SEQ ID No. 2); F178, R179, G180, I181, G182 and K183 (SEQ ID No. 3); and F180, R181, G182, H183, G184 and K185 (SEQ ID No. 7).

Particularly interesting pairwise deletions of this type are as follows:

R181\* + G182\*; and T183\* + G184\* (SEQ ID No. 1);  
20 R181\* + G182\*; and D183\* + G184\* (SEQ ID No. 2);  
R179\* + G180\*; and I181\* + G182\* (SEQ ID No. 3); and  
R181\* + G182\*; and H183\* + G184\* (SEQ ID No. 7).

(or equivalents of these pairwise deletions in another  $\alpha$ -amylase meeting the requirements of a parent  $\alpha$ -amylase in the context of the present invention).

25 Other mutations which appear to be of importance in connection with thermal stability are substitutions of one or more of the amino acid residues from P260 to I275 in the sequence shown in SEQ ID No. 1 (or equivalents thereof in another

parent  $\alpha$ -amylase in the context of the invention), such as substitution of the lysine residue in position 269.

Examples of specific mutations which appear to be of importance in connection with the thermal stability of an  $\alpha$ -amylase variant relative to the parent  $\alpha$ -amylase in question are one or more of the following substitutions in the amino acid sequence shown in SEQ ID No. 1 (or equivalents thereof in another parent  $\alpha$ -amylase in the context of the invention): K269R; P260E; R124P; M105F,I,L,V; M208F,W,Y; L217I; V206I,L,F.

For the parent  $\alpha$ -amylase having the amino acid sequence shown in SEQ ID No. 2, important further (equivalent) mutations are, correspondingly, one or more of the substitutions: M105F,I,L,V; M208F,W,Y; L217I; V206I,L,F; and K269R.

For the parent  $\alpha$ -amylase having the amino acid sequence shown in SEQ ID No. 3, important further (equivalent) mutations are, correspondingly, one or both of the substitutions: M206F,W,Y; and L215I.

15 For the parent  $\alpha$ -amylase having the amino acid sequence shown in SEQ ID No. 7, important further (equivalent) mutations are, correspondingly, one or more of the substitutions: M105F,I,L,V; M208F,W,Y; L217I; and K269R.

Still further examples of mutations which appear to be of importance, *inter alia*, in achieving improved thermal stability of an  $\alpha$ -amylase variant relative to the parent  $\alpha$ -amylase in question are one or more of the following substitutions in the amino acid sequences shown in SEQ ID No. 1, SEQ ID No. 2 and SEQ ID No. 7 (or equivalents thereof in another parent  $\alpha$ -amylase in the context of the invention): A354C + V479C; L351C + M430C; N457D,E + K385R; L355D,E + M430R,K; L355D,E + I411R,K; and N457D,E.

25 Ca<sup>2+</sup> dependency: With respect to achieving decreased Ca<sup>2+</sup> dependency of an  $\alpha$ -amylase variant relative to its parent  $\alpha$ -amylase [i.e. with respect to obtaining a

variant which exhibits satisfactory amylolytic activity in the presence of a lower concentration of calcium ion in the extraneous medium than is necessary for the parent enzyme, and which, for example, therefore is less sensitive than the parent to calcium ion-depleting conditions such as those obtaining in media containing  
5 calcium-complexing agents (such as certain detergent builders)], it appears to be particularly desirable to incorporate one or more of the following substitutions in the amino acid sequences shown in SEQ ID No. 1, SEQ ID No. 2 and SEQ ID No. 7 (or an equivalent substitution in another parent  $\alpha$ -amylase in the context of the invention): Y243F, K108R, K179R, K239R, K242R, K269R, D163N, D188N, D192N,  
10 D199N, D205N, D207N, D209N, E190Q, E194Q and N106D.

In the case of the amino acid sequence shown in SEQ ID No. 3, particularly desirable substitutions appear, correspondingly (equivalently), to be one or more of the following: K107R, K177R, K237R, K240R, D162N, D186N, D190N, D197N, D203N, D205N, D207N, E188Q and E192Q.

15 As well as the above-mentioned replacements of D residues with N residues, or of E residues with Q residues, other relevant substitutions in the context of reducing  $\text{Ca}^{2+}$  dependency are replacement of the D and/or E residues in question with any other amino acid residue.

Further substitutions which appear to be of importance in the context of achieving  
20 reduced  $\text{Ca}^{2+}$  dependency are pairwise substitutions of the amino acid residues present at: positions 113 and 151, and positions 351 and 430, in the amino acid sequences shown in SEQ ID No. 1, SEQ ID No. 2 and SEQ ID No. 7; and at: positions 112 and 150, and positions 349 and 428, in the amino acid sequence shown in SEQ ID No. 3 (or equivalent pairwise substitutions in another parent  $\alpha$ -  
25 amylase in the context of the invention), i.e. pairwise substitutions of the following amino acid residues:

G113 + N151 (in relation to SEQ ID No.1); A113 + T151 (in relation to SEQ ID No. 2 and SEQ ID No. 7); and G112 + T150 (in relation to SEQ ID No. 3); and



L351 + M430 (in relation to SEQ ID No.1, SEQ ID No. 2 and SEQ ID No. 7); and  
L349 + I428 (in relation to SEQ ID No. 3).

Particularly interesting pairwise substitutions of this type with respect to achieving decreased  $\text{Ca}^{2+}$  dependency are the following:

5 G113T + N151I (in relation to SEQ ID No.1); A113T + T151I (in relation to SEQ ID No. 2 and SEQ ID No. 7); and G112T + T150I (in relation to SEQ ID No. 3); and

L351C + M430C (in relation to SEQ ID No.1, SEQ ID No. 2 and SEQ ID No. 7); and  
L349C + I428C (in relation to SEQ ID No. 3).

In connection with substitutions of relevance for  $\text{Ca}^{2+}$  dependency, some other  
10 substitutions which appear to be of importance in stabilizing the enzyme conformation, and which it is contemplated may achieve this by, e.g., enhancing the strength of binding or retention of calcium ion at or within a calcium binding site within the  $\alpha$ -amylolytic enzyme, are one or more of the following substitutions in the amino acid sequences shown in SEQ ID No. 1, SEQ ID No. 2 and SEQ ID No. 7  
15 (or an equivalent substitution in another parent  $\alpha$ -amylase in the context of the invention): G304W,F,Y,R,I,L,V,Q,N; G305A,S,N,D,Q,E,R,K; and H408Q,E.

Corresponding (equivalent) substitutions in the amino acid sequence shown in SEQ ID No. 3 are: G302W,F,Y,R,I,L,V,Q,N; and G303A,S,N,D,Q,E,R,K.

Further mutations which appear to be of importance in the context of achieving  
20 reduced  $\text{Ca}^{2+}$  dependency are pairwise deletions of amino acids (i.e. deletion of two amino acids) at positions selected among R181, G182, T183 and G184 in the amino acid sequence shown in SEQ ID No.1 (or equivalent positions in the amino acid sequence of another  $\alpha$ -amylase meeting the requirements of a parent  $\alpha$ -amylase in the context of the invention). Such pairwise deletions are thus the  
25 following:

R181\* + G182\*; T183\* + G184\*; R181\* + T183\*; G182\* + T183\*;  
G182\* + G184\*; and R181\* + G184\* (SEQ ID No. 1);

R181\* + G182\*; D183\* + G184\*; R181\* + D183\*; G182\* + D183\*;  
G182\* + G184\*; and R181\* + G184\* (SEQ ID No. 2);

5 R179\* + G180\*; I181\* + G182\*; R179\* + I181\*; G180\* + I181\*;  
G180\* + G182\*; and R179\* + G182\* (SEQ ID No. 3); and

R181\* + G182\*; H183\* + G184\*; R181\* + H183\*; G182\* + H183\*;  
G182\* + G184\*; and R181\* + G184\* (SEQ ID No. 7);

(or equivalents of these pairwise deletions in another  $\alpha$ -amylase meeting the  
10 requirements of a parent  $\alpha$ -amylase in the context of the present invention).

Isoelectric point (pI): Preliminary results indicate that the washing performance, e.g. the laundry washing performance, of an  $\alpha$ -amylase is optimal when the pH of the washing liquor (washing medium) is close to the pI value for the  $\alpha$ -amylase in question. It will thus be desirable, where appropriate, to produce an  $\alpha$ -amylase  
15 variant having an isoelectric point (pI value) which is better matched to the pH of a medium (such as a washing medium) in which the enzyme is to be employed than the isoelectric point of the parent  $\alpha$ -amylase in question.

With respect to decreasing the isoelectric point, preferred mutations in the amino acid sequence shown in SEQ ID No. 1 include one or more of the following  
20 substitutions: Q86E, R124P, S154D, T183D, V222E, P260E, R310A, Q346E, Q391E, N437E, K444Q and R452H. Appropriate combinations of these substitutions in the context of decreasing the isoelectric point include: Q391E + K444Q; and Q391E + K444Q + S154D.

Correspondingly, preferred mutations in the amino acid sequence shown in SEQ ID  
25 No. 3 with respect to decreasing the isoelectric point include one or more of the

substitutions: L85E, S153D, I181D, K220E, P258E, R308A, P344E, Q358E and S435E.

With respect to increasing the isoelectric point, preferred mutations in the amino acid sequence shown in SEQ ID No. 2 include one or more of the following  
5 substitutions: E86Q,L; D154S; D183T,I; E222V,K; E260P; A310R; E346Q,P; E437N,S; and H452R.

In the Experimental section below, the construction of a number of variants according to the invention is described.

$\alpha$ -Amylase variants of the invention will, apart from having one or more improved  
10 properties as discussed above, preferably be such that they have a higher starch hydrolysis velocity at low substrate concentrations than the parent  $\alpha$ -amylase. Alternatively, an  $\alpha$ -amylase variant of the invention will preferably be one which has a higher  $V_{\max}$  and/or a lower  $K_m$  than the parent  $\alpha$ -amylase when tested under the same conditions. In the case of a hybrid  $\alpha$ -amylase, the "parent  $\alpha$ -amylase" to be  
15 used for the comparison should be the one of the constituent enzymes having the best performance.

$V_{\max}$  and  $K_m$  (parameters of the Michaelis-Menten equation) may be determined by well-known procedures.

#### Methods of preparing $\alpha$ -amylase variants

20 Several methods for introducing mutations into genes are known in the art. After a brief discussion of the cloning of  $\alpha$ -amylase-encoding DNA sequences, methods for generating mutations at specific sites within the  $\alpha$ -amylase-encoding sequence will be discussed.

#### Cloning a DNA sequence encoding an $\alpha$ -amylase

25 The DNA sequence encoding a parent  $\alpha$ -amylase may be isolated from any cell or microorganism producing the  $\alpha$ -amylase in question, using various methods well

- known in the art. First, a genomic DNA and/or cDNA library should be constructed using chromosomal DNA or messenger RNA from the organism that produces the  $\alpha$ -amylase to be studied. Then, if the amino acid sequence of the  $\alpha$ -amylase is known, homologous, labelled oligonucleotide probes may be synthesized and used  
5 to identify  $\alpha$ -amylase-encoding clones from a genomic library prepared from the organism in question. Alternatively, a labelled oligonucleotide probe containing sequences homologous to a known  $\alpha$ -amylase gene could be used as a probe to identify  $\alpha$ -amylase-encoding clones, using hybridization and washing conditions of lower stringency.
- 10 Yet another method for identifying  $\alpha$ -amylase-encoding clones would involve inserting fragments of genomic DNA into an expression vector, such as a plasmid, transforming  $\alpha$ -amylase-negative bacteria with the resulting genomic DNA library, and then plating the transformed bacteria onto agar containing a substrate for  $\alpha$ -amylase, thereby allowing clones expressing the  $\alpha$ -amylase to be identified.
- 15 Alternatively, the DNA sequence encoding the enzyme may be prepared synthetically by established standard methods, e.g. the phosphoramidite method described by S.L. Beaucage and M.H. Caruthers (1981) or the method described by Matthes et al. (1984). In the phosphoramidite method, oligonucleotides are synthesized, e.g. in an automatic DNA synthesizer, purified, annealed, ligated and  
20 cloned in appropriate vectors.
- Finally, the DNA sequence may be of mixed genomic and synthetic origin, mixed synthetic and cDNA origin or mixed genomic and cDNA origin, prepared by ligating fragments of synthetic, genomic or cDNA origin (as appropriate, the fragments corresponding to various parts of the entire DNA sequence), in accordance with  
25 standard techniques. The DNA sequence may also be prepared by polymerase chain reaction (PCR) using specific primers, for instance as described in US 4,683,202 or R.K. Saiki et al. (1988).

#### Site-directed mutagenesis

Once an  $\alpha$ -amylase-encoding DNA sequence has been isolated, and desirable sites for mutation identified, mutations may be introduced using synthetic oligonucleotides. These oligonucleotides contain nucleotide sequences flanking the  
5 desired mutation sites; mutant nucleotides are inserted during oligonucleotide synthesis. In a specific method, a single-stranded gap of DNA, bridging the  $\alpha$ -amylase-encoding sequence, is created in a vector carrying the  $\alpha$ -amylase gene. Then the synthetic nucleotide, bearing the desired mutation, is annealed to a homologous portion of the single-stranded DNA. The remaining gap is then filled in  
10 with DNA polymerase I (Klenow fragment) and the construct is ligated using T4 ligase. A specific example of this method is described in Morinaga et al. (1984). US 4,760,025 discloses the introduction of oligonucleotides encoding multiple mutations by performing minor alterations of the cassette. However, an even greater variety of mutations can be introduced at any one time by the Morinaga method, because  
15 a multitude of oligonucleotides, of various lengths, can be introduced.

Another method of introducing mutations into  $\alpha$ -amylase-encoding DNA sequences is described in Nelson and Long (1989). It involves the 3-step generation of a PCR fragment containing the desired mutation introduced by using a chemically synthesized DNA strand as one of the primers in the PCR reactions. From the PCR-  
20 generated fragment, a DNA fragment carrying the mutation may be isolated by cleavage with restriction endonucleases and reinserted into an expression plasmid.

#### Random mutagenesis

Random mutagenesis is suitably performed either as localized or region-specific random mutagenesis in at least three parts of the gene translating to the amino acid  
25 sequence shown in question, or within the whole gene.

For region-specific random mutagenesis with a view to improving the thermal stability, the following codon positions, in particular, may appropriately be targeted (using one-letter amino acid abbreviations and the numbering of the amino acid residues in the sequence in question):

In the amino acid sequence shown in SEQ ID No. 1:

120-140 = VEVNRSNRNQETSGEYAIEAW

178-187 = YKFRGTGKAW

264-277 = VAEFWKNDLGALEN

5 In the amino acid sequence shown in SEQ ID No. 2:

120-140 = VEVNPNNRNQEISGDYTIEAW

178-187 = YKFRGDGKAW

264-277 = VAEFWKNDLGALEN

In the amino acid sequence shown in SEQ ID No. 3:

10 119-139 = VEVNPSDRNQEISGTYQIQAW

176-185 = YKFRGIGKAW

262-275 = VGEYWSYDINKLHN

In the amino acid sequence shown in SEQ ID No. 7:

120-140 = VEVNPNNRNQEVTGEYTIEAW

15 178-187 = YKFRGHGKAW

264-277 = VAEFWKNDLGALEN

With a view to achieving reduced  $\text{Ca}^{2+}$  dependency, the following codon positions, in particular, may appropriately be targetted:

In the amino acid sequence shown in SEQ ID No. 1:

20 178-209 = YKFRGTGKAWDWEVDTENGNYDYLMYADVDM

237-246 = AVKHIKYSFT

In the amino acid sequence shown in SEQ ID No. 2:

178-209 = YKFRGDGKAWDWEVDSENGNYDYLMYADVDM

237-246 = AVKHIKYSFT

25 In the amino acid sequence shown in SEQ ID No. 7:

178-209 = YKFRGHGKAWDWEVDTENGNYDYLMYADIDMD

237-246 = AVKHIKYSFT

With a view to achieving improved binding of a substrate (i.e. improved binding of a carbohydrate species - such as amylose or amylopectin - which is a substrate for  $\alpha$ -amylolytic enzymes) by an  $\alpha$ -amylase variant, modified (e.g. higher) substrate specificity and/or modified (e.g. higher) specificity with respect to cleavage (hydrolysis) of substrate, it appears that the following codon positions for the amino acid sequence shown in SEQ ID No. 1 (or equivalent codon positions for another parent  $\alpha$ -amylase in the context of the invention) may particularly appropriately be targeted:

In the amino acid sequence shown in SEQ ID No. 1:

15-20 = WYLPND

52-58 = SQNDVGY

72-78 = KGTVRTK

15 104-111 = VMNHKGGA

165-174 = TDWDQSRQLQ

194-204 = ENGNYDYLMYA

234-240 = RIDAVKH

332-340 = HDSQPGEAL

20 The random mutagenesis of a DNA sequence encoding a parent  $\alpha$ -amylase to be performed in accordance with step a) of the above-described method of the invention may conveniently be performed by use of any method known in the art. For instance, the random mutagenesis may be performed by use of a suitable physical or chemical mutagenizing agent, by use of a suitable oligonucleotide, or  
25 by subjecting the DNA sequence to PCR generated mutagenesis. Furthermore, the random mutagenesis may be performed by use of any combination of these mutagenizing agents.

The mutagenizing agent may, e.g., be one which induces transitions, transversions, inversions, scrambling, deletions, and/or insertions.

Examples of a physical or chemical mutagenizing agent suitable for the present purpose include ultraviolet (UV) irradiation, hydroxylamine, N-methyl-N'-nitro-N-  
5 nitrosoguanidine (MNNG), O-methyl hydroxylamine, nitrous acid, ethyl methane sulphonate (EMS), sodium bisulphite, formic acid, and nucleotide analogues.

When such agents are used, the mutagenesis is typically performed by incubating the DNA sequence encoding the parent enzyme to be mutagenized in the presence of the mutagenizing agent of choice under suitable conditions for the mutagenesis  
10 to take place, and selecting for mutated DNA having the desired properties.

When the mutagenesis is performed by the use of an oligonucleotide, the oligonucleotide may be doped or spiked with the three non-parent nucleotides during the synthesis of the oligonucleotide at the positions which are to be changed. The doping or spiking may be done so that codons for unwanted amino acids are  
15 avoided. The doped or spiked oligonucleotide can be incorporated into the DNA encoding the amylolytic enzyme by any published technique, using e.g. PCR, LCR, or any DNA polymerase and ligase.

When PCR-generated mutagenesis is used, either a chemically treated or non-treated gene encoding a parent  $\alpha$ -amylase enzyme is subjected to PCR under  
20 conditions that increase the misincorporation of nucleotides (Deshler 1992; Leung et al., Technique, Vol.1, 1989, pp. 11-15).

A mutator strain of *E. coli* (Fowler et al., Molec. Gen. Genet., 133, 1974, pp. 179-191), *S. cerevisiae* or any other microbial organism may be used for the random mutagenesis of the DNA encoding the amylolytic enzyme by e.g. transforming a  
25 plasmid containing the parent enzyme into the mutator strain, growing the mutator strain with the plasmid and isolating the mutated plasmid from the mutator strain.



The mutated plasmid may subsequently be transformed into the expression organism.

The DNA sequence to be mutagenized may conveniently be present in a genomic or cDNA library prepared from an organism expressing the parent amylolytic 5 enzyme. Alternatively, the DNA sequence may be present on a suitable vector such as a plasmid or a bacteriophage, which as such may be incubated with or otherwise exposed to the mutagenizing agent. The DNA to be mutagenized may also be present in a host cell either by being integrated in the genome of said cell or by being present on a vector harboured in the cell. Finally, the DNA to be mutagenized 10 may be in isolated form. It will be understood that the DNA sequence to be subjected to random mutagenesis is preferably a cDNA or a genomic DNA sequence.

In some cases it may be convenient to amplify the mutated DNA sequence prior to the expression step (b) or the screening step (c) being performed. Such 15 amplification may be performed in accordance with methods known in the art, the presently preferred method being PCR-generated amplification using oligonucleotide primers prepared on the basis of the DNA or amino acid sequence of the parent enzyme.

Subsequent to the incubation with or exposure to the mutagenizing agent, the 20 mutated DNA is expressed by culturing a suitable host cell carrying the DNA sequence under conditions allowing expression to take place. The host cell used for this purpose may be one which has been transformed with the mutated DNA sequence, optionally present on a vector, or one which was carried the DNA sequence encoding the parent enzyme during the mutagenesis treatment. Examples 25 of suitable host cells are the following: grampositive bacteria such as *Bacillus subtilis*, *Bacillus licheniformis*, *Bacillus lentus*, *Bacillus brevis*, *Bacillus stearothermophilus*, *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus coagulans*, *Bacillus circulans*, *Bacillus lautus*, *Bacillus megaterium*, *Bacillus*

*thuringiensis*, *Streptomyces lividans* or *Streptomyces murinus*; and gramnegative bacteria such as *E.coli*.

The mutated DNA sequence may further comprise a DNA sequence encoding functions permitting expression of the mutated DNA sequence.

- 5 Localized random mutagenesis: the random mutagenesis may advantageously be localized to a part of the parent  $\alpha$ -amylase in question. This may, e.g., be advantageous when certain regions of the enzyme have been identified to be of particular importance for a given property of the enzyme, and when modified are expected to result in a variant having improved properties. Such regions may  
10 normally be identified when the tertiary structure of the parent enzyme has been elucidated and related to the function of the enzyme.

The localized random mutagenesis is conveniently performed by use of PCR-generated mutagenesis techniques as described above or any other suitable technique known in the art.

- 15 Alternatively, the DNA sequence encoding the part of the DNA sequence to be modified may be isolated, e.g. by being inserted into a suitable vector, and said part may subsequently be subjected to mutagenesis by use of any of the mutagenesis methods discussed above.

With respect to the screening step in the above-mentioned method of the invention,  
20 this may conveniently performed by use of a filter assay based on the following principle:

A microorganism capable of expressing the mutated amylolytic enzyme of interest is incubated on a suitable medium and under suitable conditions for the enzyme to be secreted, the medium being provided with a double filter comprising a first  
25 protein-binding filter and on top of that a second filter exhibiting a low protein binding capability. The microorganism is located on the second filter. Subsequent

to the incubation, the first filter comprising enzymes secreted from the microorganisms is separated from the second filter comprising the microorganisms. The first filter is subjected to screening for the desired enzymatic activity and the corresponding microbial colonies present on the second filter are identified.

- 5 The filter used for binding the enzymatic activity may be any protein binding filter e.g. nylon or nitrocellulose. The topfilter carrying the colonies of the expression organism may be any filter that has no or low affinity for binding proteins e.g. cellulose acetate or Durapore™. The filter may be pretreated with any of the conditions to be used for screening or may be treated during the detection of  
10 enzymatic activity.

The enzymatic activity may be detected by a dye, fluorescence, precipitation, pH indicator, IR-absorbance or any other known technique for detection of enzymatic activity.

- The detecting compound may be immobilized by any immobilizing agent e.g.  
15 agarose, agar, gelatine, polyacrylamide, starch, filter paper, cloth; or any combination of immobilizing agents.

- $\alpha$ -Amylase activity is detected by Cibacron Red labelled amylopectin, which is immobilized on agarose. For screening for variants with increased thermal and high-pH stability, the filter with bound  $\alpha$ -amylase variants is incubated in a buffer at pH  
20 10.5 and 60° or 65°C for a specified time, rinsed briefly in deionized water and placed on the amylopectin-agarose matrix for activity detection. Residual activity is seen as lysis of Cibacron Red by amylopectin degradation. The conditions are chosen to be such that activity due to the  $\alpha$ -amylase having the amino acid sequence shown in SEQ ID No.1 can barely be detected. Stabilized variants show,  
25 under the same conditions, increased colour intensity due to increased liberation of Cibacron Red.

For screening for variants with an activity optimum at a lower temperature and/or over a broader temperature range, the filter with bound variants is placed directly on the amylopectin-Cibacron Red substrate plate and incubated at the desired temperature (e.g. 4°C, 10°C or 30°C) for a specified time. After this time activity  
5 due to the  $\alpha$ -amylase having the amino acid sequence shown in SEQ ID No.1 can barely be detected, whereas variants with optimum activity at a lower temperature will show increase amylopectin lysis. Prior to incubation onto the amylopectin matrix, incubation in all kinds of desired media - e.g. solutions containing  $\text{Ca}^{2+}$ , detergents, EDTA or other relevant additives - can be carried out in order to screen  
10 for changed dependency or for reaction of the variants in question with such additives.

#### Methods of preparing hybrid $\alpha$ -amylases

As an alternative to site-specific mutagenesis,  $\alpha$ -amylase variants which are hybrids of at least two constituent  $\alpha$ -amylases may be prepared by combining the relevant  
15 parts of the respective genes in question.

Naturally occurring enzymes may be genetically modified by random or site directed mutagenesis as described above. Alternatively, part of one enzyme may be replaced by a part of another to obtain a chimeric enzyme. This replacement can be achieved either by conventional *in vitro* gene splicing techniques or by *in vivo*  
20 recombination or by combinations of both techniques. When using conventional *in vitro* gene splicing techniques, a desired portion of the  $\alpha$ -amylase gene coding sequence may be deleted using appropriate site-specific restriction enzymes; the deleted portion of the coding sequence may then be replaced by the insertion of a desired portion of a different  $\alpha$ -amylase coding sequence so that a chimeric  
25 nucleotide sequence encoding a new  $\alpha$ -amylase is produced. Alternatively,  $\alpha$ -amylase genes may be fused, e.g. by use of the PCR overlay extension method described by Higuchi et al. 1988.

The *in vivo* recombination techniques depend on the fact that different DNA segments with highly homologous regions (identity of DNA sequence) may

recombine, i.e. break and exchange DNA, and establish new bonds in the homologous regions. Accordingly, when the coding sequences for two different but homologous amylase enzymes are used to transform a host cell, recombination of homologous sequences *in vivo* will result in the production of chimeric gene  
5 sequences. Translation of these coding sequences by the host cell will result in production of a chimeric amylase gene product. Specific *in vivo* recombination techniques are described in US 5,093,257 and EP 252 666.

Alternatively, the hybrid enzyme may be synthesized by standard chemical methods known in the art. For example, see Hunkapiller et al. (1984). Accordingly, peptides  
10 having the appropriate amino acid sequences may be synthesized in whole or in part and joined to form hybrid enzymes (variants) of the invention.

#### Expression of $\alpha$ -amylase variants

According to the invention, a mutated  $\alpha$ -amylase-encoding DNA sequence produced by methods described above, or by any alternative methods known in the art, can  
15 be expressed, in enzyme form, using an expression vector which typically includes control sequences encoding a promoter, operator, ribosome binding site, translation initiation signal, and, optionally, a repressor gene or various activator genes.

The recombinant expression vector carrying the DNA sequence encoding an  $\alpha$ -amylase variant of the invention may be any vector which may conveniently be  
20 subjected to recombinant DNA procedures, and the choice of vector will often depend on the host cell into which it is to be introduced. Thus, the vector may be an autonomously replicating vector, i.e. a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g. a plasmid, a bacteriophage or an extrachromosomal element, minichromosome  
25 or an artificial chromosome. Alternatively, the vector may be one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated.

In the vector, the DNA sequence should be operably connected to a suitable promoter sequence. The promoter may be any DNA sequence which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell. Examples of  
5 suitable promoters for directing the transcription of the DNA sequence encoding an  $\alpha$ -amylase variant of the invention, especially in a bacterial host, are the promoter of the *lac* operon of *E.coli*, the *Streptomyces coelicolor* agarase gene *dagA* promoters, the promoters of the *Bacillus licheniformis*  $\alpha$ -amylase gene (*amyL*), the promoters of the *Bacillus stearothermophilus* maltogenic amylase gene (*amyM*), the  
10 promoters of the *Bacillus Amyloliquefaciens*  $\alpha$ -amylase (*amyQ*), the promoters of the *Bacillus subtilis* *xylA* and *xylB* genes etc. For transcription in a fungal host, examples of useful promoters are those derived from the gene encoding *A. oryzae* TAKA amylase, *Rhizomucor miehei* aspartic proteinase, *A. niger* neutral  $\alpha$ -amylase, *A. niger* acid stable  $\alpha$ -amylase, *A. niger* glucoamylase, *Rhizomucor miehei* lipase,  
15 *A. oryzae* alkaline protease, *A. oryzae* triose phosphate isomerase or *A. nidulans* acetamidase.

The expression vector of the invention may also comprise a suitable transcription terminator and, in eukaryotes, polyadenylation sequences operably connected to the DNA sequence encoding the  $\alpha$ -amylase variant of the invention. Termination and  
20 polyadenylation sequences may suitably be derived from the same sources as the promoter.

The vector may further comprise a DNA sequence enabling the vector to replicate in the host cell in question. Examples of such sequences are the origins of replication of plasmids pUC19, pACYC177, pUB110, pE194, pAMB1 and pIJ702.

25 The vector may also comprise a selectable marker, e.g. a gene the product of which complements a defect in the host cell, such as the *dal* genes from *B. subtilis* or *B. licheniformis*, or one which confers antibiotic resistance such as ampicillin, kanamycin, chloramphenicol or tetracyclin resistance. Furthermore, the vector may comprise *Aspergillus* selection markers such as *amdS*, *argB*, *niaD* and *sC*, a marker

giving rise to hygromycin resistance, or the selection may be accomplished by co-transformation, e.g. as described in WO 91/17243.

While intracellular expression may be advantageous in some respects, e.g. when using certain bacteria as host cells, it is generally preferred that the expression is  
5 extracellular.

Procedures suitable for constructing vectors of the invention encoding an  $\alpha$ -amylase variant, and containing the promoter, terminator and other elements, respectively, are well known to persons skilled in the art [cf., for instance, Sambrook et al. (1989)].

10 The cell of the invention, either comprising a DNA construct or an expression vector of the invention as defined above, is advantageously used as a host cell in the recombinant production of an  $\alpha$ -amylase variant of the invention. The cell may be transformed with the DNA construct of the invention encoding the variant, conveniently by integrating the DNA construct (in one or more copies) in the host chromo-  
15 some. This integration is generally considered to be an advantage as the DNA sequence is more likely to be stably maintained in the cell. Integration of the DNA constructs into the host chromosome may be performed according to conventional methods, e.g. by homologous or heterologous recombination. Alternatively, the cell may be transformed with an expression vector as described above in connection  
20 with the different types of host cells.

The cell of the invention may be a cell of a higher organism such as a mammal or an insect, but is preferably a microbial cell, e.g. a bacterial or a fungal (including yeast) cell.

Examples of suitable bacteria are grampositive bacteria such as *Bacillus subtilis*,  
25 *Bacillus licheniformis*, *Bacillus lentus*, *Bacillus brevis*, *Bacillus stearothermophilus*, *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus coagulans*, *Bacillus circulans*, *Bacillus lautus*, *Bacillus megaterium*, *Bacillus thuringiensis*, or

*Streptomyces lividans* or *Streptomyces murinus*, or gramnegative bacteria such as *E.coli*. The transformation of the bacteria may, for instance, be effected by protoplast transformation or by using competent cells in a manner known *per se*.

The yeast organism may favourably be selected from a species of *Saccharomyces* 5 or *Schizosaccharomyces*, e.g. *Saccharomyces cerevisiae*. The filamentous fungus may advantageously belong to a species of *Aspergillus*, e.g. *Aspergillus oryzae* or *Aspergillus niger*. Fungal cells may be transformed by a process involving protoplast formation and transformation of the protoplasts followed by regeneration of the cell wall in a manner known *per se*. A suitable procedure for transformation of 10 *Aspergillus* host cells is described in EP 238 023.

In a yet further aspect, the present invention relates to a method of producing an  $\alpha$ -amylase variant of the invention, which method comprises cultivating a host cell as described above under conditions conducive to the production of the variant and recovering the variant from the cells and/or culture medium.

15 The medium used to cultivate the cells may be any conventional medium suitable for growing the host cell in question and obtaining expression of the  $\alpha$ -amylase variant of the invention. Suitable media are available from commercial suppliers or may be prepared according to published recipes (e.g. as described in catalogues of the American Type Culture Collection).

20 The  $\alpha$ -amylase variant secreted from the host cells may conveniently be recovered from the culture medium by well-known procedures, including separating the cells from the medium by centrifugation or filtration, and precipitating proteinaceous components of the medium by means of a salt such as ammonium sulphate, followed by the use of chromatographic procedures such as ion exchange 25 chromatography, affinity chromatography, or the like.



### Industrial Applications

Owing to their activity at alkaline pH values,  $\alpha$ -amylase variants of the invention are well suited for use in a variety of industrial processes. In particular, they find potential applications as a component in washing, dishwashing and hard surface  
5 cleaning detergent compositions (*vide infra*), but may also be useful in the production of sweeteners and ethanol from starch. Conditions for conventional starch-converting processes and liquefaction and/or saccharification processes are described in, for instance, US 3,912,590, EP 252,730 and EP 63,909.

Some areas of application of  $\alpha$ -amylase variants of the invention are outlined below.

- 10 Paper-related applications:  $\alpha$ -Amylase variants of the invention possess properties of value in the production of lignocellulosic materials, such as pulp, paper and cardboard, from starch-reinforced waste paper and waste cardboard, especially where repulping occurs at a pH above 7, and where amylases can facilitate the disintegration of the waste material through degradation of the reinforcing starch.
- 15  $\alpha$ -Amylase variants of the invention are well suited for use in the deinking/recycling processes of making paper out of starch-coated or starch-containing waste printed paper. It is usually desirable to remove the printing ink in order to produce new paper of high brightness; examples of how the variants of the invention may be used in this way are described in PCT/DK94/00437.
- 20  $\alpha$ -Amylase variants of the invention may also be very useful in modifying starch where enzymatically modified starch is used in papermaking together with alkaline fillers such as calcium carbonate, kaolin and clays. With alkaline  $\alpha$ -amylase variants of the invention it is feasible to modify the starch in the presence of the filler, thus allowing for a simpler, integrated process.
- 25 Textile desizing:  $\alpha$ -Amylase variants of the invention are also well suited for use in textile desizing. In the textile processing industry,  $\alpha$ -amylases are traditionally used as auxiliaries in the desizing process to facilitate the removal of starch-containing size which has served as a protective coating on weft yarns during weaving.

Complete removal of the size coating after weaving is important to ensure optimum results in subsequent processes in which the fabric is scoured, bleached and dyed. Enzymatic starch degradation is preferred because it does not harm the fibres of the textile or fabric.

5 In order to reduce processing costs and increase mill throughput, the desizing processing is sometimes combined with the scouring and bleaching steps. In such cases, non-enzymatic auxiliaries such as alkali or oxidation agents are typically used to break down the starch, because traditional  $\alpha$ -amylases are not very compatible with high pH levels and bleaching agents. The non-enzymatic  
10 breakdown of the starch size does lead to some fibre damage because of the rather aggressive chemicals used.

$\alpha$ -Amylase variants of the invention exhibiting improved starch-degrading performance at relatively high pH levels and in the presence of oxidizing (bleaching) agents are thus well suited for use in desizing processes as described above, in  
15 particular for replacement of non-enzymatic desizing agents currently used. The  $\alpha$ -amylase variant may be used alone, or in combination with a cellulase when desizing cellulose-containing fabric or textile.

Beer production:  $\alpha$ -Amylase variants of the invention are also believed to be very useful in beer-making processes; in such processes the variants will typically be  
20 added during the mashing process.

Applications in detergent additives and detergent compositions for washing or dishwashing: Owing to the improved washing and/or dishwashing performance which will often be a consequence of improvements in properties as discussed above, numerous  $\alpha$ -amylase variants (including hybrids) of the invention are particu-  
25 larly well suited for incorporation into detergent compositions, e.g. detergent compositions intended for performance in the pH range of 7-13, particularly the pH range of 8-11. According to the invention, the  $\alpha$ -amylase variant may be added as

a component of a detergent composition. As such, it may be included in the detergent composition in the form of a detergent additive.

Thus, a further aspect of the invention relates to a detergent additive comprising an  $\alpha$ -amylase variant according to the invention. The enzymes may be included in a detergent composition by adding separate additives containing one or more enzymes, or by adding a combined additive comprising all of these enzymes. A detergent additive of the invention, i.e. a separated additive or a combined additive, can be formulated, e.g., as a granulate, liquid, slurry, etc. Preferred enzyme formulations for detergent additives are granulates (in particular non-dusting granulates), liquids (in particular stabilized liquids), slurries or protected enzymes (*vide infra*).

The detergent composition as well as the detergent additive may additionally comprise one or more other enzymes conventionally used in detergents, such as proteases, lipases, amylolytic enzymes, oxidases (including peroxidases), or cellulases.

It has been found that substantial improvements in washing and/or dishwashing performance may be obtained when  $\alpha$ -amylase is combined with another amylolytic enzyme, such as a pullulanase, an iso-amylase, a beta-amylase, an amyloglucosidase or a CTGase. Examples of commercially available amylolytic enzymes suitable for the given purpose are AMG<sup>TM</sup>, Novamyl<sup>TM</sup> and Promozyme<sup>TM</sup>, all of which available from Novo Nordisk A/S, Bagsvaerd, Denmark. Accordingly, a particular embodiment of the invention relates to a detergent additive comprising an  $\alpha$ -amylase variant of the invention in combination with at least one other amylolytic enzyme (e.g. chosen amongst those mentioned above).

Non-dusting granulates may be produced, e.g., as disclosed in US 4,106,991 and US 4,661,452, and may optionally be coated by methods known in the art; further details concerning coatings are given below. When a combination of different

detergent enzymes is to be employed, the enzymes may be mixed before or after granulation.

Liquid enzyme preparations may, for instance, be stabilized by adding a polyol such as propylene glycol, a sugar or sugar alcohol, lactic acid or boric acid according to 5 established methods. Other enzyme stabilizers are well known in the art. Protected enzymes may be prepared according to the method disclosed in EP 238 216.

As already indicated, a still further aspect of the invention relates to a detergent composition, e.g. for laundry washing, for dishwashing or for hard-surface cleaning, comprising an  $\alpha$ -amylase variant (including hybrid) of the invention, and a 10 surfactant.

The detergent composition of the invention may be in any convenient form, e.g. as powder, granules or liquid. A liquid detergent may be aqueous, typically containing up to 90% of water and 0-20% of organic solvent, or non-aqueous, e.g. as described in EP Patent 120,659.

#### 15 Detergent Compositions

When an  $\alpha$ -amylase variant of the invention is employed as a component of a detergent composition (e.g. a laundry washing detergent composition, or a dishwashing detergent composition), it may, for example, be included in the detergent composition in the form of a non-dusting granulate, a stabilized liquid, or 20 a protected enzyme. As mentioned above, non-dusting granulates may be produced, e.g., as disclosed in US 4,106,991 and 4,661,452 (both to Novo Industri A/S) and may optionally be coated by methods known in the art. Examples of waxy coating materials are poly(ethylene oxide) products (polyethyleneglycol, PEG) with mean molecular weights of 1000 to 20000; ethoxylated nonylphenols having from 25 16 to 50 ethylene oxide units; ethoxylated fatty alcohols in which the alcohol contains from 12 to 20 carbon atoms and in which there are 15 to 80 ethylene oxide units; fatty alcohols; fatty acids; and mono- and di- and triglycerides of fatty acids.

Examples of film-forming coating materials suitable for application by fluid bed techniques are given in GB 1483591.

Enzymes added in the form of liquid enzyme preparations may, as indicated above, be stabilized by, e.g., the addition of a polyol such as propylene glycol, a sugar or  
5 sugar alcohol, lactic acid or boric acid according to established methods. Other enzyme stabilizers are well known in the art.

Protected enzymes for inclusion in a detergent composition of the invention may be prepared, as mentioned above, according to the method disclosed in EP 238,216.

The detergent composition of the invention may be in any convenient form, e.g. as  
10 powder, granules, paste or liquid. A liquid detergent may be aqueous, typically containing up to 70% water and 0-30% organic solvent, or nonaqueous.

The detergent composition comprises one or more surfactants, each of which may be anionic, nonionic, cationic, or amphoteric (zwitterionic). The detergent will usually contain 0-50% of anionic surfactant such as linear alkylbenzenesulfonate (LAS),  
15 alpha-olefinsulfonate (AOS), alkyl sulfate (fatty alcohol sulfate) (AS), alcohol ethoxysulfate (AEOS or AES), secondary alkanesulfonates (SAS), alpha-sulfo fatty acid methyl esters, alkyl- or alkenylsuccinic acid, or soap. It may also contain 0-40% of nonionic surfactant such as alcohol ethoxylate (AEO or AE), alcohol propoxylate, carboxylated alcohol ethoxylates, nonylphenol ethoxylate, alkylpolyglycoside,  
20 alkyldimethylamine oxide, ethoxylated fatty acid monoethanolamide, fatty acid monoethanolamide, or polyhydroxy alkyl fatty acid amide (e.g. as described in WO 92/06154).

The detergent composition may additionally comprise one or more other enzymes, such as pullulanase, esterase, lipase, cutinase, protease, cellulase, peroxidase, or  
25 oxidase, e.g., laccase.

Normally the detergent contains 1-65% of a detergent builder (although some dishwashing detergents may contain even up to 90% of a detergent builder) or complexing agent such as zeolite, diphosphate, triphosphate, phosphonate, citrate, nitrilotriacetic acid (NTA), ethylenediaminetetraacetic acid (EDTA), diethylenetri-  
5 aminepentaacetic acid (DTMPA), alkyl- or alkenylsuccinic acid, soluble silicates or layered silicates (e.g. SKS-6 from Hoechst).

The detergent builders may be subdivided into phosphorus-containing and non-phosphorous-containing types. Examples of phosphorus-containing inorganic alkaline detergent builders include the water-soluble salts, especially alkali metal  
10 pyrophosphates, orthophosphates, polyphosphates and phosphonates. Examples of non-phosphorus-containing inorganic builders include water-soluble alkali metal carbonates, borates and silicates, as well as layered disilicates and the various types of water-insoluble crystalline or amorphous alumino silicates of which zeolites are the best known representatives.

15 Examples of suitable organic builders include alkali metal, ammonium or substituted ammonium salts of succinates, malonates, fatty acid malonates, fatty acid sulphonates, carboxymethoxy succinates, polyacetates, carboxylates, polycarboxylates, aminopolycarboxylates and polyacetyl carboxylates.

The detergent may also be unbuilt, i.e. essentially free of detergent builder.

20 The detergent may comprise one or more polymers. Examples are carboxymethylcellulose (CMC; typically in the form of the sodium salt), poly(vinylpyrrolidone) (PVP), polyethyleneglycol (PEG), poly(vinyl alcohol) (PVA), polycarboxylates such as polyacrylates, polymaleates, maleic/acrylic acid copolymers and lauryl methacrylate/acrylic acid copolymers.

25 The detergent composition may contain bleaching agents of the chlorine/bromine-type or the oxygen-type. The bleaching agents may be coated or encapsulated. Examples of inorganic chlorine/bromine-type bleaches are lithium, sodium or

calcium hypochlorite or hypobromite as well as chlorinated trisodium phosphate. The bleaching system may also comprise a  $H_2O_2$  source such as perborate or percarbonate which may be combined with a peracid-forming bleach activator such as tetraacetythylenediamine (TAED) or nonanoyloxybenzenesulfonate (NOBS).

5 Examples of organic chlorine/bromine-type bleaches are heterocyclic N-bromo and N-chloro imides such as trichloroisocyanuric, tribromoisocyanuric, dibromoisocyanuric and dichloroisocyanuric acids, and salts thereof with water solubilizing cations such as potassium and sodium. Hydantoin compounds are also suitable. The bleaching system may also comprise peroxyacids of, e.g., the amide,  
10 imide, or sulfone type.

In dishwashing detergents the oxygen bleaches are preferred, for example in the form of an inorganic persalt, preferably with a bleach precursor or as a peroxy acid compound. Typical examples of suitable peroxy bleach compounds are alkali metal perborates, both tetrahydrates and monohydrates, alkali metal percarbonates,  
15 persilicates and perphosphates. Preferred activator materials are TAED or NOBS.

The enzymes of the detergent composition of the invention may be stabilized using conventional stabilizing agents, e.g. a polyol such as propylene glycol or glycerol, a sugar or sugar alcohol, lactic acid, boric acid, or a boric acid derivative such as, e.g., an aromatic borate ester, and the composition may be formulated as described  
20 in, e.g., WO 92/19709 and WO 92/19708. The enzymes of the invention may also be stabilized by adding reversible enzyme inhibitors, e.g., of the protein type (as described in EP 0 544 777 B1) or the boronic acid type.

The detergent may also contain other conventional detergent ingredients such as, e.g., fabric conditioners including clays, deflocculant material, foam boosters/foam  
25 depressors (in dishwashing detergents foam depressors), suds suppressors, anti-corrosion agents, soil-suspending agents, anti-soil-redeposition agents, dyes, dehydrating agents, bactericides, optical brighteners, or perfume.

The pH (measured in aqueous solution at use concentration) will usually be neutral or alkaline, e.g. in the range of 7-11.

Particular forms of laundry detergent compositions within the scope of the invention include:

- 5 1) A detergent composition formulated as a granulate having a bulk density of at least 600 g/l comprising

	Linear alkylbenzenesulfonate (calculated as acid)	7 - 12%
10	Alcohol ethoxysulfate (e.g. C <sub>12-18</sub> alcohol, 1-2 EO) or alkyl sulfate (e.g. C <sub>16-18</sub> )	1 - 4%
	Alcohol ethoxylate (e.g. C <sub>14-15</sub> alcohol, 7 EO)	5 - 9%
	Sodium carbonate (as Na <sub>2</sub> CO <sub>3</sub> )	14 - 20%
	Soluble silicate (as Na <sub>2</sub> O,2SiO <sub>2</sub> )	2 - 6%
	Zeolite (as NaAlSiO <sub>4</sub> )	15 - 22%
15	Sodium sulfate (as Na <sub>2</sub> SO <sub>4</sub> )	0 - 6%
	Sodium citrate/citric acid (as C <sub>6</sub> H <sub>5</sub> Na <sub>3</sub> O <sub>7</sub> /C <sub>6</sub> H <sub>8</sub> O <sub>7</sub> )	0 - 15%
	Sodium perborate (as NaBO <sub>3</sub> ·H <sub>2</sub> O)	11 - 18%
	TAED	2 - 6%
20	Carboxymethylcellulose	0 - 2%
	Polymers (e.g. maleic/acrylic acid copolymer, PVP, PEG)	0 - 3%
	Enzymes (calculated as pure enzyme protein)	0.0001 - 0.1%
25	Minor ingredients (e.g. suds suppressors, perfume, optical brightener, photobleach)	0 - 5%



2) A detergent composition formulated as a granulate having a bulk density of at least 600 g/l comprising

	Linear alkylbenzenesulfonate (calculated as acid)	6 - 11%
5	Alcohol ethoxysulfate (e.g. C <sub>12-18</sub> alcohol, 1-2 EO or alkyl sulfate (e.g. C <sub>16-18</sub> ))	1 - 3%
	Alcohol ethoxylate (e.g. C <sub>14-15</sub> alcohol, 7 EO)	5 - 9%
	Sodium carbonate (as Na <sub>2</sub> CO <sub>3</sub> )	15 - 21%
10	Soluble silicate (as Na <sub>2</sub> O,2SiO <sub>2</sub> )	1 - 4%
	Zeolite (as NaAlSiO <sub>4</sub> )	24 - 34%
	Sodium sulfate (as Na <sub>2</sub> SO <sub>4</sub> )	4 - 10%
	Sodium citrate/citric acid (as C <sub>6</sub> H <sub>5</sub> Na <sub>3</sub> O <sub>7</sub> /C <sub>6</sub> H <sub>8</sub> O <sub>7</sub> )	0 - 15%
15	Carboxymethylcellulose	0 - 2%
	Polymers (e.g. maleic/acrylic acid copolymer, PVP, PEG)	1 - 6%
	Enzymes (calculated as pure enzyme protein)	0.0001 - 0.1%
20	Minor ingredients (e.g. suds suppressors, perfume)	0 - 5%

3) A detergent composition formulated as a granulate having a bulk density of at least 600 g/l comprising

25	Linear alkylbenzenesulfonate (calculated as acid)	5 - 9%
	Alcohol ethoxylate (e.g. C <sub>12-15</sub> alcohol, 7 EO)	7 - 14%
	Soap as fatty acid (e.g. C <sub>16-22</sub> fatty acid)	1 - 3%
	Sodium carbonate (as Na <sub>2</sub> CO <sub>3</sub> )	10 - 17%
	Soluble silicate (as Na <sub>2</sub> O,2SiO <sub>2</sub> )	3 - 9%
30	Zeolite (as NaAlSiO <sub>4</sub> )	23 - 33%
	Sodium sulfate (as Na <sub>2</sub> SO <sub>4</sub> )	0 - 4%

	Sodium perborate (as $\text{NaBO}_3 \cdot \text{H}_2\text{O}$ )	8 - 16%
	TAED	2 - 8%
	Phosphonate (e.g. EDTMPA)	0 - 1%
	Carboxymethylcellulose	0 - 2%
5	Polymers (e.g. maleic/acrylic acid copolymer, PVP, PEG)	0 - 3%
	Enzymes (calculated as pure enzyme protein)	0.0001 - 0.1%
10	Minor ingredients (e.g. suds suppressors, perfume, optical brightener)	0 - 5%

4) A detergent composition formulated as a granulate having a bulk density of at least 600 g/l comprising

	Linear alkylbenzenesulfonate (calculated as acid)	8 - 12%
15	Alcohol ethoxylate (e.g. $\text{C}_{12-15}$ alcohol, 7 EO)	10 - 25%
	Sodium carbonate (as $\text{Na}_2\text{CO}_3$ )	14 - 22%
	Soluble silicate (as $\text{Na}_2\text{O} \cdot 2\text{SiO}_2$ )	1 - 5%
	Zeolite (as $\text{NaAlSiO}_4$ )	25 - 35%
	Sodium sulfate (as $\text{Na}_2\text{SO}_4$ )	0 - 10%
20	Carboxymethylcellulose	0 - 2%
	Polymers (e.g. maleic/acrylic acid copolymer, PVP, PEG)	1 - 3%
	Enzymes (calculated as pure enzyme protein)	0.0001 - 0.1%
25	Minor ingredients (e.g. suds suppressors, perfume)	0 - 5%

## 5) An aqueous liquid detergent composition comprising

	Linear alkylbenzenesulfonate (calculated as acid)	15	- 21%
5	Alcohol ethoxylate (e.g. C <sub>12-15</sub> alcohol, 7 EO or C <sub>12-15</sub> alcohol, 5 EO)	12	- 18%
	Soap as fatty acid (e.g. oleic acid)	3	- 13%
	Alkenylsuccinic acid (C <sub>12-14</sub> )	0	- 13%
	Aminoethanol	8	- 18%
	Citric acid	2	- 8%
10	Phosphonate	0	- 3%
	Polymers (e.g. PVP, PEG)	0	- 3%
	Borate (as B <sub>4</sub> O <sub>7</sub> <sup>2-</sup> )	0	- 2%
	Ethanol	0	- 3%
	Propylene glycol	8	- 14%
15	Enzymes (calculated as pure enzyme protein)	0.0001	- 0.1%
	Minor ingredients (e.g. dispersants, suds suppressors, perfume, optical brightener)	0	- 5%

## 6) An aqueous structured liquid detergent composition comprising

	Linear alkylbenzenesulfonate (calculated as acid)	15	- 21%
5	Alcohol ethoxylate (e.g. C <sub>12-15</sub> alcohol, 7 EO, or C <sub>12-15</sub> alcohol, 5 EO)	3	- 9%
	Soap as fatty acid (e.g. oleic acid)	3	- 10%
	Zeolite (as NaAlSiO <sub>4</sub> )	14	- 22%
	Potassium citrate	9	- 18%
	Borate (as B <sub>4</sub> O <sub>7</sub> <sup>2-</sup> )	0	- 2%
10	Carboxymethylcellulose	0	- 2%
	Polymers (e.g. PEG, PVP)	0	- 3%
	Anchoring polymers such as, e.g., lauryl methacrylate/acrylic acid copolymer; molar ratio 25:1; MW 3800	0	- 3%
15	Glycerol	0	- 5%
	Enzymes (calculated as pure enzyme protein)	0.0001	- 0.1%
	Minor ingredients (e.g. dispersants, suds suppressors, perfume, optical brighteners)	0	- 5%

## 20 7) A detergent composition formulated as a granulate having a bulk density of at least 600 g/l comprising

	Fatty alcohol sulfate	5	- 10%
	Ethoxylated fatty acid monoethanolamide	3	- 9%
	Soap as fatty acid	0	- 3%
25	Sodium carbonate (as Na <sub>2</sub> CO <sub>3</sub> )	5	- 10%
	Soluble silicate (as Na <sub>2</sub> O, 2SiO <sub>2</sub> )	1	- 4%
	Zeolite (as NaAlSiO <sub>4</sub> )	20	- 40%
	Sodium sulfate (as Na <sub>2</sub> SO <sub>4</sub> )	2	- 8%
	Sodium perborate (as NaBO <sub>3</sub> ·H <sub>2</sub> O)	12	- 18%
30	TAED	2	- 7%

	Polymers (e.g. maleic/acrylic acid copolymer, PEG)	1 - 5%
	Enzymes (calculated as pure enzyme protein)	0.0001 - 0.1%
5	Minor ingredients (e.g. optical brightener, suds suppressors, perfume)	0 - 5%

8) A detergent composition formulated as a granulate comprising

	Linear alkylbenzenesulfonate (calculated as acid)	8 - 14%
10	Ethoxylated fatty acid monoethanolamide	5 - 11%
	Soap as fatty acid	0 - 3%
	Sodium carbonate (as $\text{Na}_2\text{CO}_3$ )	4 - 10%
	Soluble silicate (as $\text{Na}_2\text{O} \cdot 2\text{SiO}_2$ )	1 - 4%
	Zeolite (as $\text{NaAlSiO}_4$ )	30 - 50%
15	Sodium sulfate (as $\text{Na}_2\text{SO}_4$ )	3 - 11%
	Sodium citrate (as $\text{C}_6\text{H}_5\text{Na}_3\text{O}_7$ )	5 - 12%
	Polymers (e.g. PVP, maleic/acrylic acid copolymer, PEG)	1 - 5%
	Enzymes (calculated as pure enzyme protein)	0.0001 - 0.1%
20	Minor ingredients (e.g. suds suppressors, perfume)	0 - 5%

9) A detergent composition formulated as a granulate comprising

25	Linear alkylbenzenesulfonate (calculated as acid)	6 - 12%
	Nonionic surfactant	1 - 4%
	Soap as fatty acid	2 - 6%
	Sodium carbonate (as $\text{Na}_2\text{CO}_3$ )	14 - 22%
	Zeolite (as $\text{NaAlSiO}_4$ )	18 - 32%
30	Sodium sulfate (as $\text{Na}_2\text{SO}_4$ )	5 - 20%
	Sodium citrate (as $\text{C}_6\text{H}_5\text{Na}_3\text{O}_7$ )	3 - 8%

	Sodium perborate (as $\text{NaBO}_3 \cdot \text{H}_2\text{O}$ )	4 - 9%
	Bleach activator (e.g. NOBS or TAED)	1 - 5%
	Carboxymethylcellulose	0 - 2%
	Polymers (e.g. polycarboxylate or PEG)	1 - 5%
5	Enzymes (calculated as pure enzyme protein)	0.0001 - 0.1%
	Minor ingredients (e.g. optical brightener, perfume)	0 - 5%

10) An aqueous liquid detergent composition comprising

10	Linear alkylbenzenesulfonate (calculated as acid)	15 - 23%
	Alcohol ethoxysulfate (e.g. $\text{C}_{12-15}$ alcohol, 2-3 EO)	8 - 15%
15	Alcohol ethoxylate (e.g. $\text{C}_{12-15}$ alcohol, 7 EO, or $\text{C}_{12-15}$ alcohol, 5 EO)	3 - 9%
	Soap as fatty acid (e.g. lauric acid)	0 - 3%
	Aminoethanol	1 - 5%
	Sodium citrate	5 - 10%
	Hydrotrope (e.g. sodium toluenesulfonate)	2 - 6%
20	Borate (as $\text{B}_4\text{O}_7^{2-}$ )	0 - 2%
	Carboxymethylcellulose	0 - 1%
	Ethanol	1 - 3%
	Propylene glycol	2 - 5%
25	Enzymes (calculated as pure enzyme protein)	0.0001 - 0.1%
	Minor ingredients (e.g. polymers, dispersants, perfume, optical brighteners)	0 - 5%

## 11) An aqueous liquid detergent composition comprising

	Linear alkylbenzenesulfonate (calculated as acid)	20	- 32%
5	Alcohol ethoxylate (e.g. C <sub>12-15</sub> alcohol, 7 EO, or C <sub>12-15</sub> alcohol, 5 EO)	6	- 12%
	Aminoethanol	2	- 6%
	Citric acid	8	- 14%
	Borate (as B <sub>4</sub> O <sub>7</sub> <sup>2-</sup> )	1	- 3%
10	Polymer (e.g. maleic/acrylic acid copolymer, anchoring polymer such as, e.g., lauryl methacrylate/acrylic acid copolymer)	0	- 3%
	Glycerol	3	- 8%
	Enzymes (calculated as pure enzyme protein)	0.0001	- 0.1%
15	Minor ingredients (e.g. hydrotropes, dispersants, perfume, optical brighteners)	0	- 5%

## 12) A detergent composition formulated as a granulate having a bulk density of at least 600 g/l comprising

20	Anionic surfactant (linear alkylbenzene-sulfonate, alkyl sulfate, alpha-olefinsulfonate, alpha-sulfo fatty acid methyl esters, alkanesulfonates, soap)	25	- 40%
	Nonionic surfactant (e.g. alcohol ethoxylate)	1	- 10%
25	Sodium carbonate (as Na <sub>2</sub> CO <sub>3</sub> )	8	- 25%
	Soluble silicates (as Na <sub>2</sub> O, 2SiO <sub>2</sub> )	5	- 15%
	Sodium sulfate (as Na <sub>2</sub> SO <sub>4</sub> )	0	- 5%
	Zeolite (as NaAlSiO <sub>4</sub> )	15	- 28%
	Sodium perborate (as NaBO <sub>3</sub> ·4H <sub>2</sub> O)	0	- 20%
30	Bleach activator (TAED or NOBS)	0	- 5%
	Enzymes (calculated as pure enzyme protein)	0.0001	- 0.1%

Minor ingredients (e.g. perfume, optical brighteners)	0 - 3%
---	--------

13) Detergent formulations as described in 1) - 12) wherein all or part of the linear alkylbenzenesulfonate is replaced by (C<sub>12</sub>-C<sub>18</sub>) alkyl sulfate.

5 14) A detergent composition formulated as a granulate having a bulk density of at least 600 g/l comprising

	(C <sub>12</sub> -C <sub>18</sub> ) alkyl sulfate	9 - 15%
	Alcohol ethoxylate	3 - 6%
	Polyhydroxy alkyl fatty acid amide	1 - 5%
10	Zeolite (as NaAlSiO <sub>4</sub> )	10 - 20%
	Layered disilicate (e.g. SK56 from Hoechst)	10 - 20%
	Sodium carbonate (as Na <sub>2</sub> CO <sub>3</sub> )	3 - 12%
	Soluble silicate (as Na <sub>2</sub> O,2SiO <sub>2</sub> )	3 - 6%
	Sodium citrate	4 - 8%
15	Sodium percarbonate	13 - 22%
	TAED	3 - 8%
	Polymers (e.g. polycarboxylates and PVP)	0 - 5%
	Enzymes (calculated as pure enzyme protein)	0.0001 - 0.1%
20	Minor ingredients (e.g. optical brightener, photo bleach, perfume, suds suppressors)	0 - 5%

15) A detergent composition formulated as a granulate having a bulk density of at least 600 g/l comprising

	(C <sub>12</sub> -C <sub>18</sub> ) alkyl sulfate	4 - 8%
25	Alcohol ethoxylate	11 - 15%
	Soap	1 - 4%



	Zeolite MAP or zeolite A	35 - 45%
	Sodium carbonate (as $\text{Na}_2\text{CO}_3$ )	2 - 8%
	Soluble silicate (as $\text{Na}_2\text{O}, 2\text{SiO}_2$ )	0 - 4%
	Sodium percarbonate	13 - 22%
5	TAED	1 - 8%
	Carboxymethyl cellulose	0 - 3%
	Polymers (e.g. polycarboxylates and PVP)	0 - 3%
	Enzymes (calculated as pure enzyme protein)	0.0001 - 0.1%
10	Minor ingredients (e.g. optical brightener, phosphonate, perfume)	0 - 3%

16) Detergent formulations as described in 1) - 15) which contain a stabilized or encapsulated peracid, either as an additional component or as a substitute for already specified bleach systems.

15 17) Detergent compositions as described in 1), 3), 7), 9) and 12) wherein perborate is replaced by percarbonate.

18) Detergent compositions as described in 1), 3), 7), 9), 12), 14) and 15) which additionally contain a manganese catalyst. The manganese catalyst may, e.g., be one of the compounds described in "Efficient manganese catalysts for low-  
20 temperature bleaching", Nature 369, 1994, pp. 637-639.

19) Detergent composition formulated as a nonaqueous detergent liquid comprising a liquid nonionic surfactant such as, e.g., linear alkoxylated primary alcohol, a builder system (e.g. phosphate), enzyme and alkali. The detergent may also comprise anionic surfactant and/or a bleach system.

25 Particular forms of dishwashing detergent compositions within the scope of the invention include:

## 1) POWDER AUTOMATIC DISHWASHING COMPOSITION

	Nonionic surfactant	0.4 - 2.5%
	Sodium metasilicate	0 - 20%
	Sodium disilicate	3 - 20%
5	Sodium triphosphate	20 - 40%
	Sodium carbonate	3 - 20%
	Sodium perborate	2 - 9%
	Tetraacetylenediamine (TAED)	1 - 4%
	Sodium sulphate	5 - 33%
10	Enzymes	0.0001 - 0.1%

## 2) POWDER AUTOMATIC DISHWASHING COMPOSITION

	Nonionic surfactant (e.g. alcohol ethoxylate)	1 - 2%
	Sodium disilicate	2 - 30%
15	Sodium carbonate	10 - 50%
	Sodium phosphonate	0 - 5%
	Trisodium citrate dihydrate	9 - 30%
	Nitrilotrisodium acetate (NTA)	0 - 20%
	Sodium perborate monohydrate	5 - 10%
20	Tetraacetylenediamine (TAED)	1 - 2%
	Polyacrylate polymer (e.g. maleic acid/acrylic acid copolymer)	6 - 25%
	Enzymes	0.0001 - 0.1%
	Perfume	0.1 - 0.5%
25	Water	5 - 10

## 3) POWDER AUTOMATIC DISHWASHING COMPOSITION

Nonionic surfactant	0.5 - 2.0%
---------------------	------------

	Sodium disilicate	25	- 40%
	Sodium citrate	30	- 55%
	Sodium carbonate	0	- 29%
	Sodium bicarbonate	0	- 20%
5	Sodium perborate monohydrate	0	- 15%
	Tetraacetylenediamine (TAED)	0	- 6%
	Maleic acid/acrylic acid copolymer	0	- 5%
	Clay	1	- 3%
10	Poly(amino acids)	0	- 20%
	Sodium polyacrylate	0	- 8%
	Enzymes	0.0001	- 0.1%

## 4) POWDER AUTOMATIC DISHWASHING COMPOSITION

	Nonionic surfactant	1	- 2%
15	Zeolite MAP	15	- 42%
	Sodium disilicate	30	- 34%
	Sodium citrate	0	- 12%
	Sodium carbonate	0	- 20%
	Sodium perborate monohydrate	7	- 15%
20	Tetraacetylenediamine (TAED)	0	- 3%
	Polymer	0	- 4%
	Maleic acid/acrylic acid copolymer	0	- 5%
	Organic phosphonate	0	- 4%
	Clay	1	- 2%
25	Enzymes	0.0001	- 0.1%
	Sodium sulphate	Balance	

## 5) POWDER AUTOMATIC DISHWASHING COMPOSITION

	Nonionic surfactant	1	- 7%
	Sodium disilicate	18	- 30%
	Trisodium citrate	10	- 24%
5	Sodium carbonate	12	- 20%
	Monopersulphate (2 KHSO <sub>5</sub> ·KHSO <sub>4</sub> ·K <sub>2</sub> SO <sub>4</sub> )	15	- 21%
	Bleach stabilizer	0.1	- 2%
	Maleic acid/acrylic acid copolymer	0	- 6%
10	Diethylenetriaminepentaacetate, pentasodium salt	0	- 2.5%
	Enzymes	0.0001	- 0.1%
	Sodium sulphate, water	Balance	

## 6) POWDER AND LIQUID DISHWASHING COMPOSITION WITH CLEANING SURFACTANT SYSTEM

15	Nonionic surfactant	0	- 1.5%
	Octadecyl dimethylamine N-oxide dihydrate	0	- 5%
	80:20 wt.C18/C16 blend of octadecyl dimethylamine N-oxide dihydrate and hexadecyldimethyl amine N-oxide dihydrate	0	- 4%
20	70:30 wt.C18/C16 blend of octadecyl bis (hydroxyethyl)amine N-oxide anhydrous and hexadecyl bis (hydroxyethyl)amine N-oxide anhydrous	0	- 5%
25	C <sub>13</sub> -C <sub>15</sub> alkyl ethoxysulfate with an average degree of ethoxylation of 3	0	- 10%
	C <sub>12</sub> -C <sub>15</sub> alkyl ethoxysulfate with an average degree of ethoxylation of 3	0	- 5%
	C <sub>13</sub> -C <sub>15</sub> ethoxylated alcohol with an average degree of ethoxylation of 12	0	- 5%
30	A blend of C <sub>12</sub> -C <sub>15</sub> ethoxylated alcohols with an average degree of ethoxylation of 9	0	- 6.5%

	A blend of C <sub>13</sub> -C <sub>15</sub> ethoxylated alcohols with an average degree of ethoxylation of 30	0 - 4%
	Sodium disilicate	0 - 33%
	Sodium tripolyphosphate	0 - 46%
5	Sodium citrate	0 - 28%
	Citric acid	0 - 29%
	Sodium carbonate	0 - 20%
	Sodium perborate monohydrate	0 - 11.5%
	Tetraacetythylenediamine (TAED)	0 - 4%
10	Maleic acid/acrylic acid copolymer	0 - 7.5%
	Sodium sulphate	0 - 12.5%
	Enzymes	0.0001 - 0.1%

## 7) NON-AQUEOUS LIQUID AUTOMATIC DISHWASHING COMPOSITION

15	Liquid nonionic surfactant (e.g. alcohol ethoxylates)	2.0 - 10.0%
	Alkali metal silicate	3.0 - 15.0%
	Alkali metal phosphate	20.0 - 40.0%
	Liquid carrier selected from higher glycols, polyglycols, polyoxides, glycolethers	25.0 - 45.0%
20	Stabilizer (e.g. a partial ester of phosphoric acid and a C <sub>16</sub> -C <sub>18</sub> alkanol)	0.5 - 7.0%
	Foam suppressor (e.g. silicone)	0 - 1.5%
	Enzymes	0.0001 - 0.1%

## 8) NON-AQUEOUS LIQUID DISHWASHING COMPOSITION

25	Liquid nonionic surfactant (e.g. alcohol ethoxylates)	2.0 - 10.0%
	Sodium silicate	3.0 - 15.0%
	Alkali metal carbonate	7.0 - 20.0%
	Sodium citrate	0.0 - 1.5%

5	Stabilizing system (e.g. mixtures of finely divided silicone and low molecular weight dialkyl polyglycol ethers)	0.5 - 7.0%
	Low molecule weight polyacrylate polymer	5.0 - 15.0%
	Clay gel thickener (e.g. bentonite)	0.0 - 10.0%
	Hydroxypropyl cellulose polymer	0.0 - 0.6%
	Enzymes	0.0001 - 0.1%
	Liquid carrier selected from higher lycols, polyglycols, polyoxides and glycol ethers	Balance

## 10 9) THIXOTROPIC LIQUID AUTOMATIC DISHWASHING COMPOSITION

15	C <sub>12</sub> -C <sub>14</sub> fatty acid	0 - 0.5%
	Block co-polymer surfactant	1.5 - 15.0%
	Sodium citrate	0 - 12%
	Sodium tripolyphosphate	0 - 15%
	Sodium carbonate	0 - 8%
	Aluminium tristearate	0 - 0.1%
	Sodium cumene sulphonate	0 - 1.7%
	Polyacrylate thickener	1.32 - 2.5%
	Sodium polyacrylate	2.4 - 6.0%
	Boric acid	0 - 4.0%
20	Sodium formate	0 - 0.45%
	Calcium formate	0 - 0.2%
	Sodium n-decydiphenyl oxide disulphonate	0 - 4.0%
	Monoethanol amine (MEA)	0 - 1.86%
	Sodium hydroxide (50%)	1.9 - 9.3%
	1,2-Propanediol	0 - 9.4%
	Enzymes	0.0001 - 0.1%
	Suds suppressor, dye, perfumes, water	Balance

## 10) LIQUID AUTOMATIC DISHWASHING COMPOSITION

	Alcohol ethoxylate	0	- 20%
	Fatty acid ester sulphonate	0	- 30%
	Sodium dodecyl sulphate	0	- 20%
5	Alkyl polyglycoside	0	- 21%
	Oleic acid	0	- 10%
	Sodium disilicate monohydrate	18	- 33%
	Sodium citrate dihydrate	18	- 33%
	Sodium stearate	0	- 2.5%
10	Sodium perborate monohydrate	0	- 13%
	Tetraacetythylenediamine (TAED)	0	- 8%
	Maleic acid/acrylic acid copolymer	4	- 8%
	Enzymes	0.0001	- 0.1%

11) LIQUID AUTOMATIC DISHWASHING COMPOSITION CONTAINING  
15 PROTECTED BLEACH PARTICLES

	Sodium silicate	5	- 10%
	Tetrapotassium pyrophosphate	15	- 25%
	Sodium triphosphate	0	- 2%
	Potassium carbonate	4	- 8%
20	Protected bleach particles, e.g. chlorine	5	- 10%
	Polymeric thickener	0.7	- 1.5%
	Potassium hydroxide	0	- 2%
	Enzymes	0.0001	- 0.1%
	Water	Balance	

25 11) Automatic dishwashing compositions as described in 1), 2), 3), 4), 6) and 10), wherein perborate is replaced by percarbonate.

12) Automatic dishwashing compositions as described in 1) - 6) which additionally contain a manganese catalyst. The manganese catalyst may, e.g., be one of the compounds described in "Efficient manganese catalysts for low-temperature bleaching", Nature 369, 1994, pp. 637-639.

5 An  $\alpha$ -amylase variant of the invention may be incorporated in concentrations conventionally employed in detergents. It is at present contemplated that, in the detergent composition of the invention, the  $\alpha$ -amylase variant may be added in an amount corresponding to 0.00001-1 mg (calculated as pure enzyme protein) of  $\alpha$ -amylase per liter of wash/dishwash liquor.

10 The present invention is further described with reference to the appended drawing, in which:

Fig. 1 is an alignment of the amino acid sequences of four parent  $\alpha$ -amylases in the context of the invention. The numbers on the extreme left designate the respective amino acid sequences as follows:

- 15        1: the amino acid sequence shown in SEQ ID No. 1;  
          2: the amino acid sequence shown in SEQ ID No. 2;  
          3: the amino acid sequence shown in SEQ ID No. 3; and  
          4: the amino acid sequence shown in SEQ ID No. 7.

The numbers on the extreme right of the figure give the running total number of  
20 amino acids for each of the sequences in question. It should be noted that for the sequence numbered 3 (corresponding to the amino acid sequence shown in SEQ ID No. 3), the alignment results in "gaps" at the positions corresponding to amino acid No. 1 and amino acid No. 175, respectively, in the sequences numbered 1 (SEQ ID No. 1), 2 (SEQ ID No. 2) and 4 (SEQ ID No. 7).

25 Fig. 2 is a restriction map of plasmid pTVB106.

Fig. 3 is a restriction map of plasmid pPM103.



Fig. 4 is a restriction map of plasmid pTVB112.

Fig. 5 is a restriction map of plasmid pTVB114.

## EXPERIMENTAL SECTION

The preparation, purification and sequencing of the parent  $\alpha$ -amylases having the amino acid sequences shown in SEQ ID No. 1 and SEQ ID No. 2 (from *Bacillus* strains NCIB 12512 and NCIB 12513, respectively) is described in WO 95/26397.

- 5 The pI values and molecular weights of these two parent  $\alpha$ -amylases (given in WO 95/26397) are as follows:

SEQ ID No. 1: pI about 8.8-9.0 (determined by isoelectric focusing on LKB Ampholine™ PAG plates); molecular weight approximately 55 kD (determined by SDS-PAGE).

- 10 SEQ ID No. 2: pI about 5.8 (determined by isoelectric focusing on LKB Ampholine™ PAG plates); molecular weight approximately 55 kD (determined by SDS-PAGE).

### Purification of $\alpha$ -amylase variants of the invention

- The construction and expression of variants according to the invention is described in Example 2, below. The purification of variants of the invention is illustrated here  
15 with reference to variants of the amino acid sequences shown in SEQ ID No. 1 and SEQ ID No. 2, respectively:

Purification of SEQ ID No. 1 variants (pI approx. 9.0): The fermentation liquid containing the expressed  $\alpha$ -amylase variant is filtered, and ammonium sulfate is added to a concentration of 15% of saturation. The liquid is then applied onto a  
20 hydrophobic column (Toyopearl butyl/TOSOH). The column is washed with 20 mM dimethyl-glutaric acid buffer, pH 7.0. The  $\alpha$ -amylase is bound very tightly, and is eluted with 25% w/w 2-propanol in 20 mM dimethylglutaric acid buffer, pH 7.0. After elution, the 2-propanol is removed by evaporation and the concentrate is applied onto a cation exchanger (S-Sepharose™ FF, Pharmacia, Sweden) equilibrated with  
25 20 mM dimethylglutaric acid buffer, pH 6.0.

The amylase is eluted using a linear gradient of 0-250 mM NaCl in the same buffer. After dialysis against 10 mM borate/KCl buffer, pH 8.0, the sample is adjusted to pH 9.6 and applied to an anion exchanger (Q-Sepharose™ FF, Pharmacia) equilibrated with 10 mM borate/KCl buffer, pH 9.6. The amylase is eluted using a linear gradient of 0-250 mM NaCl. The pH is adjusted to 7.5. The  $\alpha$ -amylase is pure as judged by rSDS-PAGE. All buffers contain 2mM  $\text{CaCl}_2$  in order to stabilize the amylase.

Purification of SEQ ID No. 2 variants (pI approx. 5.8): The fermentation liquid containing the expressed  $\alpha$ -amylase variant is filtered, and ammonium sulfate is added to a concentration of 15% of saturation. The liquid is then applied onto a hydrophobic column (Toyopearl butyl/TOSOH). The bound amylase is eluted with a linear gradient of 15%-0% w/w ammonium sulfate in 10 mM Tris buffer, pH 8.0. After dialysis of the eluate against 10 mM borate/KCl buffer, pH 8.0, the liquid is adjusted to pH 9.6 and applied onto an anion exchanger (Q-Sepharose™ FF, Pharmacia) equilibrated with the same buffer. The amylase is step-eluted using 150 mM NaCl.

After elution the amylase sample is dialysed against the same buffer, pH 8.0, in order to remove the NaCl. After dialysis, the pH is adjusted to 9.6 and the amylase is bound once more onto the anion exchanger. The amylase is eluted using a linear gradient of 0-250 mM NaCl. The pH is adjusted to 7.5. The amylase is pure as judged by rSDS-PAGE. All buffers contain 2 mM  $\text{CaCl}_2$  in order to stabilize the amylase.

#### Determination of $\alpha$ -amylase activity

$\alpha$ -Amylase activity is determined by a method employing Phadebas® tablets as substrate. Phadebas tablets (Phadebas® Amylase Test, supplied by Pharmacia Diagnostic) contain a cross-linked insoluble blue-coloured starch polymer which has been mixed with bovine serum albumin and a buffer substance and tabletted.

For the determination of every single measurement one tablet is suspended in a tube containing 5 ml 50 mM Britton-Robinson buffer (50 mM acetic acid, 50 mM

phosphoric acid, 50 mM boric acid, 0.1 mM  $\text{CaCl}_2$ , pH adjusted to the value of interest with NaOH). The test is performed in a water bath at the temperature of interest. The  $\alpha$ -amylase to be tested is diluted in x ml of 50 mM Britton-Robinson buffer. 1 ml of this  $\alpha$ -amylase solution is added to the 5 ml 50 mM Britton-Robinson  
5 buffer. The starch is hydrolysed by the  $\alpha$ -amylase giving soluble blue fragments. The absorbance of the resulting blue solution, measured spectrophotometrically at 620 nm, is a function of the  $\alpha$ -amylase activity.

It is important that the measured 620 nm absorbance after 15 minutes of incubation (testing time) is in the range of 0.2 to 2.0 absorbance units at 620 nm. In this  
10 absorbance range there is linearity between activity and absorbance (Lambert-Beer law). The dilution of the enzyme must therefore be adjusted to fit this criterion.

Under a specified set of conditions (temp., pH, reaction time, buffer conditions) 1 mg of a given  $\alpha$ -amylase will hydrolyse a certain amount of substrate and a blue colour will be produced. The colour intensity is measured at 620 nm. The measured  
15 absorbance is directly proportional to the specific activity (activity/mg of pure  $\alpha$ -amylase protein) of the  $\alpha$ -amylase in question under the given set of conditions. Thus testing different  $\alpha$ -amylases of interest (including a reference  $\alpha$ -amylase, in this case the parent  $\alpha$ -amylase in question) under identical conditions, the specific activity of each of the  $\alpha$ -amylases at a given temperature and at a given pH can be  
20 compared directly, and the ratio of the specific activity of each of the  $\alpha$ -amylases of interest relative to the specific activity of the reference  $\alpha$ -amylase can be determined.

#### Mini dishwashing assay

The following mini dishwashing assay was used: A suspension of starchy material was boiled and cooled to 20°C. The cooled starch suspension was applied on small, individually identified glass plates (approx. 2 x 2 cm) and dried at a temperature of ca. 140°C in a drying cabinet. The individual plates were then weighed. For assay purposes, a solution of standard European-type automatic dishwashing detergent (5 g/l) having a temperature of 55°C was prepared. The detergent was allowed a dissolution time of 1 minute, after which the  $\alpha$ -amylase in question was added to the detergent solution (contained in a beaker equipped with magnetic stirring) so as to give an enzyme concentration of 0.5 mg/l. At the same time, the weighed glass plates, held in small supporting clamps, were immersed in a substantially vertical position in the  $\alpha$ -amylase/detergent solution, which was then stirred for 15 minutes at 55°C. The glass plates were then removed from the  $\alpha$ -amylase/detergent solution, rinsed with distilled water, dried at 60°C in a drying cabinet and re-weighed. The performance of the  $\alpha$ -amylase in question [expressed as an index relative to a chosen reference  $\alpha$ -amylase (index 100) - in the example below (Example 1) the parent  $\alpha$ -amylase having the amino acid sequence shown in SEQ ID No. 1] was then determined from the difference in weight of the glass plates before and after treatment, as follows:

$$\text{Index} = \frac{\text{weight loss for plate treated with } \alpha\text{-amylase}}{\text{weight loss for plate treated with reference}} \cdot 100$$

The following examples further illustrate the present invention. They are not intended to be in any way limiting to the scope of the invention as claimed.

#### **EXAMPLE 1**

##### 25 Mini dishwashing test of variants of parent $\alpha$ -amylase having the amino acid sequence shown in SEQ ID No. 1

The above-described mini dishwashing test was performed at pH 10.5 with the parent  $\alpha$ -amylase having the amino acid sequence shown in SEQ ID No. 1 and the

following variants thereof (the construction and purification of which is described below): T183\* + G184\*; Y243F; and K269R. The test gave the following results:

Parent (SEQ ID No. 1)	Index: 100
T183* + G184*	Index: 120
5 Y243F	Index: 120
K269R	Index: 131

It is apparent that the each of the tested variants T183\* + G184\* (which exhibits, *inter alia*, higher thermal stability than the parent  $\alpha$ -amylase), Y243F (which exhibits lower calcium ion dependency than the parent  $\alpha$ -amylase) and K269R (which  
10 exhibits lower calcium ion dependency and higher stability at high pH than the parent  $\alpha$ -amylase) exhibits significantly improved dishwashing performance relative to the parent  $\alpha$ -amylase.

## EXAMPLE 2

Construction of variants of the parent  $\alpha$ -amylases having the amino acid sequences  
15 shown in SEQ ID No. 1 and SEQ ID No. 2, respectively

Primers: DNA primers employed in the construction of variants as described below include the following [all DNA primers are written in the direction from 5' to 3' (left to right); P denotes a 5' phosphate]:

#7113:

20 GCT GCG GTG ACC TCT TTA AAA AAT AAC GGC

Y296:

CC ACC GCT ATT AGA TGC ATT GTA C

#6779:

CTT ACG TAT GCA GAC GTC GAT ATG GAT CAC CC

#6778:

G ATC CAT ATC GAC GTC TGC ATA CGT AAG ATA GTC

#3811:

TT A(C/G)G GGC AAG GCC TGG GAC TGG

5 #7449:

C CCA GGC CTT GCC C(C/G)T AAA TTT ATA TAT TTT GTT TTG

#3810:

G GTT TCG GTT CGA AGG ATT CAC TTC TAC CGC

#7450:

10 GCG GTA GAA GTG AAT CCT TCG AAC CGA AAC CAG

B1:

GGT ACT ATC GTA ACA ATG GCC GAT TGC TGA CGC TGT TAT TTG C

#6616:

P CTG TGA CTG GTG AGT ACT CAA CCA AGT C

15 #8573:

CTA CTT CCC AAT CCC AAG CTT TAC CTC GGA ATT TG

#8569:

CAA ATT CCG AGG TAA AGC TTG GGA TTG GGA AGT AG

#8570:

20 TTG AAC AAC CGT TCC ATT AAG AAG

A: Construction of variants of the parent  $\alpha$ -amylase having the amino acid sequence shown in SEQ ID No. 1

Description of plasmid pTVB106: The parent  $\alpha$ -amylase having the amino acid sequence shown in SEQ ID No. 1 and variants thereof are expressed from a 5 plasmid-borne gene, SF16, shown in Fig. 2. The plasmid, pTVB106, contains an origin of replication obtained from plasmid pUB110 (Gryczan et al., 1978) and the *cat* gene conferring resistance towards chloramphenicol. Secretion of the amylase is aided by the Termamyl™ signal sequence that is fused precisely, i.e. codon No. 1 of the mature protein, to the gene encoding the parent  $\alpha$ -amylase having the 10 nucleotide and amino acid sequence (mature protein) shown in SEQ ID No. 4 and SEQ ID No. 1, respectively. The Termamyl promoter initiates transcription of the gene.

Plasmid pTVB106 is similar to pDN1528 (see laid-open Danish patent application No. 1155/94). Some unique restriction sites are indicated on the plasmid map in 15 Fig. 2, including *Bst*BI, *Bam*HI, *Bst*EII, *Eco*NI, *Drd*I, *Afl*III, *Dra*III, *Xma*I, *Sal*I and *Bgl*II.

Construction of variant M202T: The PCR overlap extension mutagenesis method is used to construct this variant (Higuchi et al., 1988). An approximately 350 bp DNA fragment of pTVB106 is amplified in a PCR reaction A using primers #7113 20 and mutagenic primer #6778. In a similar PCR reaction B, an approximately 300 bp DNA fragment is amplified using primers Y296 and #6779. The complete DNA fragment spanning the mutation site (M202) from primer #7113 to primer Y296 is amplified in PCR C using these primers and purified DNA fragments from reactions A and B.

25 PCR C DNA is digested with restriction endonucleases *Bst*EII and *Afl*III, and the 480 bp fragment is ligated with plasmid pTVB106 digested with the same enzymes and transformed into a low-protease and low-amylase *Bacillus subtilis* strain (e.g. strain SHA273 mentioned in WO 92/11357).



Other M202 variants are constructed in a similar manner.

Construction of variants T183\* + G184\* and R181\* + G182\*: The PCR overlap extension mutagenesis method is used to construct these variants (Higuchi et al., 1988). The mutagenic oligoneucleotides are synthesized using a mixture (equal 5 parts) of C and G in one position; two different mutations can therefore be constructed by this procedure. An approximately 300 bp DNA fragment of pTVB106 is amplified in a PCR reaction A using primers #7113 and mutagenic primer #7449. In a similar PCR reaction B, an approximately 400 bp DNA fragment is amplified using primers Y296 and #3811. The complete DNA 10 fragment spanning the mutation site (amino acids 181-184) from primer #7113 to primer Y296 is amplified in PCR C using these primers and purified DNA fragments from reactions A and B.

PCR C DNA is digested with restriction endonucleases *Bst*EII and *A*III and the 480 bp fragment is ligated with plasmid pTVB106 digested with the same enzymes and 15 transformed into a low-protease and low-amylase *B. subtilis* strain (e.g. strain SHA273 mentioned in WO 92/11357). Sequencing of plasmid DNA from these transformants identifies the two correct mutations: i.e. R181\* + G182\* and T183\* + G184\*.

Construction of variant R124P: The PCR overlap extension mutagenesis method is 20 used to construct this variant in a manner similar to the construction of variant M202T (*vide supra*). PCR reaction A (with primers #3810 and B1) generates an approximately 500 bp fragment, and PCR reaction B (primers 7450 and Y296) generates an approximately 550 bp fragment. PCR reaction C based on the product of PCR reaction A and B and primers B1 and Y296 is digested with restriction 25 endonucleases *Bst*EII and *A*III, and the resulting 480 bp fragment spanning amino acid position 124 is subcloned into pTVB106 digested with the same enzymes and transformed into *B. subtilis* as previously described.

Construction of variant R124P + T183\* + G184\*: For the construction of the variant combining the R124P and the T183\* + G184\* mutations, two *Eco*NI restriction sites (one located at position 1.774 kb, i.e. between the R124P mutation and the T183\* + G184\* mutation, and one located at position 0.146 kb) were utilized. The  
5 approximately 1630 bp *Eco*NI fragment of the pTVB106-like plasmid containing the T183\* + G184\* mutation was subcloned into the vector part (approximately 3810 bp DNA fragment containing the origin of replication) of another pTVB106-like plasmid containing the R124P mutation digested with the same enzyme. Transformation into *Bacillus subtilis* was carried out as previously described.

10 Construction of variants G182\* + G184\*; R181\* + T183\*; Y243F; K269R; and L351C + M430C: These variants were constructed as follows:

A specific mutagenesis vector containing a major part of the coding region for the amino acid sequence shown in SEQ.ID No. 1 was prepared. The important features of this vector (which is denoted pPM103) include an origin of replication derived  
15 from the pUC plasmid, the *cat* gene conferring resistance towards chloramphenicol and a frameshift-mutation-containing version of the *bla* gene, the wild-type version of which normally confers resistance towards ampicillin (amp<sup>R</sup> phenotype). This mutated version of the *bla* gene results in an amp<sup>S</sup> phenotype. The plasmid pPM103 is shown in Fig. 3, and the *E. coli* origin of replication, the 5'-truncated  
20 version of the SF16 amylase gene, and *ori*, *bla*, *cat* and selected restriction sites are indicated on the plasmid.

Mutations are introduced in the gene of interest as described by Deng and Nickoloff [Anal. Biochem. 200 (1992), pp. 81-88], except that plasmids with the "selection primer" (#6616) incorporated are selected based on the amp<sup>R</sup> phenotype of  
25 transformed *E. coli* cells harboring a plasmid with a repaired *bla* gene instead of using the selection by restriction-enzyme digestion outlined by Deng and Nickoloff. Chemicals and enzymes used for the mutagenesis were obtained from the Chameleon™ mutagenesis kit from Stratagene (catalogue number 200509).

After verification of the DNA sequence in variant plasmids, the truncated gene containing the desired alteration is subcloned from the pPM103-like plasmid into pTVB106 as an approximately 1440 bp *Bst*BI-*Sal*I fragment and transformed into *Bacillus subtilis* for expression of the variant enzyme.

- 5 For the construction of the pairwise deletion variant G182\* + G184\*, the following mutagenesis primer was used:

P CTC TGT ATC GAC TTC CCA GTC CCA AGC TTT TGT CCT GAA TTT ATA  
TAT TTT GTT TTG AAG

- For the construction of the pairwise deletion variant R181\* + T183\*, the following  
10 mutagenesis primer was used:

P CTC TGT ATC GAC TTC CCA GTC CCA AGC TTT GCC TCC GAA TTT ATA  
TAT TTT GTT TTG AAG

- For the construction of the substitution variant Y243F, the following mutagenesis  
15 primer was used:

P ATG TGT AAG CCA ATC GCG AGT AAA GCT AAA TTT TAT ATG TTT CAC  
TGC ATC

For the construction of the substitution variant K269R, the following mutagenesis  
primer was used:

- 20 P GC ACC AAG GTC ATT TCG CCA GAA TTC AGC CAC TG

For the construction of the pairwise substitution variant L351C + M430C, the  
following mutagenesis primers were used simultaneously:

- 1) P TGT CAG AAC CAA CGC GTA TGC ACA TGG TTT AAA CCA TTG

2) P ACC ACC TGG ACC ATC GCT GCA GAT GGT GGC AAG GCC TGA ATT

Construction of variant L351C + M430C + T183\* + G184\*: This variant was constructed by combining the L351C + M430C pairwise substitution mutation and the T183\* + G184\* pairwise deletion mutation by subcloning an approximately 1430 5 bp *HindIII-AflIII* fragment containing L351C + M430C into a pTVB106-like plasmid (with the T183\* + G184\* mutations) digested with the same enzymes.

Construction of variant Y243F + T183\* + G184\*: This variant was constructed by combining the Y243F mutation and the T183\* + G184\* mutation by subcloning an approximately 1148 bp *DrdI* fragment containing T183\* + G184\* into a pTVB106-like 10 plasmid (with the Y243 mutation) digested with the same enzyme.

*Bacillus subtilis* transformants were screened for  $\alpha$ -amylase activity on starch-containing agar plates and the presence of the correct mutations was checked by DNA sequencing.

Construction of variant Y243F + T183\* + G184\* + L351C + M430C: The L351C + 15 M430C pairwise substitution mutation was subcloned as an approximately 470 bp *XmaI-SaII* fragment into a pTVB106-like vector (containing Y243F + T183\* + G184\*) digested with the same enzymes.

Construction of variant Y243F + T183\* + G184\* + L351C + M430C + Q391E + K444Q: A pPM103-like vector containing the mutations Y243F + T183\* + G184\* + 20 L351C + M430C was constructed by substituting the truncated version of SF16 in pPM103 with the approximately 1440 bp *BstBI-SaII* fragment of the pTVB106-like vector containing the five mutations in question. The Q391E and K444Q mutations were introduced simultaneously into the pPM103-like vector (containing Y243F + T183\* + G184\* + L351C + M430C) by the use of the following two mutagenesis 25 primers in a manner similar to the previously described mutagenesis on pPM103:

P GGC AAA AGT TTG ACG TGC CTC GAG AAG AGG GTC TAT

P TTG TCC CGC TTT ATT CTG GCC AAC ATA CAT CCA TTT

B: Construction of variants of the parent  $\alpha$ -amylase having the amino acid sequence shown in SEQ ID No. 2

Description of plasmid pTVB112: A vector, denoted pTVB112, to be used for the  
5 expression in *B. subtilis* of the  $\alpha$ -amylase having the amino acid sequence shown  
in SEQ ID No. 2 was constructed. This vector is very similar to pTVB106 except  
that the gene encoding the mature  $\alpha$ -amylase of SEQ ID No. 2 is inserted between  
the *Pst*I and the *Hind*III sites in pTVB106. Thus, the expression of this  $\alpha$ -amylase  
(SEQ ID No. 2) is also directed by the *amy*L promoter and signal sequence. The  
10 plasmid pTVB112 is shown in Fig. 4.

Construction of variant D183\* + G184\*: The construction of this variant was  
achieved using the PCR overlap extension mutagenesis method referred to earlier  
(*vide supra*). Primers #8573 and B1 were used in PCR reaction A, and primers  
#8569 and #8570 were used in PCR reaction B. The purified fragments from  
15 reaction A and reaction B and primers 1B and #8570 were used in PCR reaction C,  
resulting in an approximately 1020 bp DNA fragment. This fragment was digested  
with restriction endonucleases *Pst*I and *Mlu*I, and subcloned into the expression  
vector and transformed into *B. subtilis*.

Construction of further variants: By analogy with the construction (*vide supra*) of the  
20 plasmid pPM103 used in the production of mutants of the amino acid sequence of  
SEQ ID No. 1, a plasmid (denoted pTVB114; shown in Fig. 5) was constructed for  
the continued mutagenesis on variant D183\* + G184\* (SEQ ID No. 2). Mutations  
were introduced in pTVB114 (SEQ ID No. 2; D183\*+G184\*) in a manner similar to  
that for pPM103 (SEQ ID No. 1).

25 For the construction of the pairwise deletion variants R181\* + D183\* and R181\* +  
G182\*, it was chosen to alter the flanking amino acids in the variant D183\* + G184\*  
instead of deleting the specified amino acids in the wild type gene for SEQ ID No.

2. The following mutagenesis primer was used for the mutagenesis with pTVB114 as template:

PCC CAA TCC CAA GCT TTA CCA (T/C)CG AAC TTG TAG ATA CG

The presence of a mixture of two bases (T/C) at one position allows for the  
5 presence of two different deletion flanking amino acid based on one mutagenesis primer. DNA sequencing of the resulting plasmids verifies the presence of either the one or the the other mutation. The mutated gene of interest is subcloned as a *Pst*I-*Dra*III fragment into pTVB112 digested with the same enzymes and transformed into *B. subtilis*.

10 For the construction of G182\* + G184\* and R181\* + G184\*, the following mutagenesis primer was used with pTVB114 as template:

PCC CAA TCC CAA GCT TTA TCT C(C/G)G AAC TTG TAG ATA CG

As before, the presence of a mixture of two bases (C/G) at one position allows for the presence of two different deletion flanking amino acid based on one  
15 mutagenesis primer. DNA sequencing of the resulting plasmids verifies the presence of either the one or the the other mutation. The mutated gene of interest is subcloned as a *Pst*I-*Dra*III fragment into pTVB112 digested with the same enzymes and transformed into *B. subtilis*.

For the construction of D183\* + G184\* + M202L the following mutagenesis primer  
20 was used:

PGA TCC ATA TCG ACG TCT GCA TAC AGT AAA TAA TC

For the construction of D183\* + G184\* + M202I the following mutagenesis primer was used:

PGA TCC ATA TCG ACG TCT GCA TAA ATT AAA TAA TC

### EXAMPLE 3

Determination of oxidation stability of M202 substitution variants of the parent  $\alpha$ -amylases having the amino acid sequences shown in SEQ ID No. 1 and SEQ ID  
5 No. 2

#### A: Oxidation stability of variants of the sequence in SEQ ID No. 1

The measurements were made using solutions of the respective variants in 50mM Britton-Robinson buffer (50 mM acetic acid, 50 mM phosphoric acid, 50 mM boric acid, 0.1 mM  $\text{CaCl}_2$ , pH adjusted to the value of interest with NaOH), pH 9.0, to  
10 which hydrogen peroxide was added (at time  $t = 0$ ) to give a final concentration of 200mM  $\text{H}_2\text{O}_2$ . The solutions were then incubated at 40°C in a water bath.

After incubation for 5, 10, 15 and 20 minutes after addition of hydrogen peroxide, the residual  $\alpha$ -amylase activity was measured using the Phadebas assay described above. The residual activity in the samples was measured using 50mM Britton-  
15 Robinson buffer, pH 7.3, at 37°C (see Novo analytical publication AF207-1/1, available on request from Novo Nordisk A/S). The decline in activity was measured relative to a corresponding reference solution of the same enzyme at 0 minutes which was not incubated with hydrogen peroxide (100% activity).

The percentage of initial activity as a function of time is shown in the table below  
20 for the parent enzyme (SEQ ID No. 1) and for the variants in question.

	Variant	% Activity after incubation for (minutes)				
		0	5	10	15	20
25	M202L	100	90	72	58	27
	M202F	100	100	87	71	43

74

M202A	100	99	82	64	30
M202I	100	91	75	59	28
M202T	100	87	65	49	20
M202V	100	100	87	74	43
5 M202S	100	100	85	68	34
Parent	100	51	26	13	2

All the M202 substitution variants tested clearly exhibit significantly improved stability towards oxidation relative to the parent  $\alpha$ -amylase (SEQ ID No. 1).

10 **B: Oxidation stability of variants of the sequence in SEQ ID No. 2**

Measurements were made as described above using the parent  $\alpha$ -amylase in question (SEQ ID No. 2), the variant M202L + D183\* + G184\* (designated L in the table below) and the variant M202I + D183\* + G184\* (designated I in the table below), respectively. In this case, incubation times (after addition of hydrogen  
15 peroxide) of 5, 10, 15 and 30 minutes were employed. As in the table above, the percentage of initial activity as a function of time is shown in the table below for the parent enzyme and for the variants in question.

Variant	% Activity after incubation for (minutes)				
	0	5	10	15	30
20 L	100	91	85	71	43
I	100	81	61	44	18
Parent	100	56	26	14	4

25

The two "substitution + pairwise deletion" variants tested (which both comprise an M202 substitution) clearly exhibit significantly improved stability towards oxidation relative to the parent  $\alpha$ -amylase (SEQ ID No. 2).



**EXAMPLE 4**

Determination of thermal stability of variants of the parent  $\alpha$ -amylases having the amino acid sequences shown in SEQ ID No. 1 and SEQ ID No. 2

A: Thermal stability of pairwise deletion variants of the sequence in

5 SEQ ID No. 1

Measurements were made using solutions of the respective variants in 50mM Britton-Robinson buffer (*vide supra*), pH 9.0. The solutions were incubated at 65°C in a water bath, and samples were withdrawn after incubation for the indicated periods of time. The residual  $\alpha$ -amylase activity of each withdrawn sample was  
 10 measured using the Phadebas assay, as described above. The decline in activity was measured relative to a corresponding reference solution of the same enzyme at 0 minutes which was not incubated (100% activity).

The percentage of initial activity as a function of time is shown in the table below for the parent enzyme (SEQ ID No. 1) and for the following pairwise deletion  
 15 variants in question:

Variant 1: R181\* + G182\*

Variant 2: R181\* + T183\*

Variant 3: G182\* + G184\*

Variant 4: T183\* + G184\*

20 Variant 5: T183\* + G184\* + R124P

Variant	% Activity after incubation for (minutes)						
	0	5	10	15	30	45	60
25 1	100	81	66	49	24	14	8
2	100	80	53	39	17	8	3
3	100	64	40	28	10	4	2

76

---

4	100	64	43	34	20	8	5
5	100	78	73	66	57	47	38
Parent	100	13	2	0	0	0	0

---

5 It is apparent that all of the pairwise deletion variants tested exhibit significantly improved thermal stability relative to the parent  $\alpha$ -amylase (SEQ ID No. 1), and that the thermal stability of Variant 5, which in addition to the pairwise deletion mutation of Variant 4 comprises the substitution R124P, is markedly higher than that of the other variants. Since calorimetric results for the substitution variant R124P  
 10 (comprising only the substitution R124P) reveal an approximately 7°C thermostabilization thereof relative to the parent  $\alpha$ -amylase, it appears that the thermostabilizing effects of the mutation R124P and the pairwise deletion, respectively, reinforce each other.

**B: Thermal stability of pairwise deletion variants of the sequence in**

15 **SEQ ID No. 2**

Corresponding measurements were made for the parent enzyme (SEQ ID No. 2) and for the following pairwise deletion variants:

Variant A: D183\* + G184\*

Variant B: R181\* + G182\*

20 Variant C: G182\* + G184\*

---

Variant	% Activity after incubation for (minutes)				
	0	5	10	15	30

---

25 A	100	87	71	63	30
B	100	113	85	76	58
C	100	99	76	62	34
Parent	100	72	55	44	18

Again, it is apparent that the pairwise deletion variants in question exhibit significantly improved thermal stability relative to the parent  $\alpha$ -amylase (SEQ ID No. 2).

C: Thermal stability of a multi-combination variant of the sequence in

5 SEQ ID No. 1

Corresponding comparative measurements were also made for the following variants of the amino acid sequence shown in SEQ ID No. 1:

Variant 4: T183\* + G184\*

Variant 6: L351C + M430C

10 Variant 7: Y243F

Variant 8: Q391E + K444Q

Variant 9: T183\* + G184\* + L351C + M430C + Y243F + Q391E + K444Q

Variant	% Activity after incubation for (minutes)				
	0	5	10	15	30
4	100	66	41	22	7
6	100	87	73	65	43
7	100	14	2	1	0
20 8	100	69	46	31	14
9	100	92	93	89	82

Again, it appears that the thermostabilizing effect of multiple mutations, each of which has a thermostabilizing effect, is - at least qualitatively - cumulative.

**EXAMPLE 5**Calcium-binding affinity of  $\alpha$ -amylase variants of the invention

Unfolding of amylases by exposure to heat or to denaturants such as guanidine hydrochloride is accompanied by a decrease in fluorescence. Loss of calcium ions leads to unfolding, and the affinity of a series of  $\alpha$ -amylases for calcium can be measured by fluorescence measurements before and after incubation of each  $\alpha$ -amylase (e.g. at a concentration of 10  $\mu$ g/ml) in a buffer (e.g. 50 mM HEPES, pH 7) with different concentrations of calcium (e.g. in the range of 1  $\mu$ M-100 mM) or of EGTA (e.g. in the range of 1-1000  $\mu$ M) [EGTA = 1,2-di(2-aminoethoxy)ethane-10 *N,N,N',N'*-tetraacetic acid] for a sufficiently long period of time (such as 22 hours at 55°C).

The measured fluorescence  $F$  is composed of contributions from the folded and unfolded forms of the enzyme. The following equation can be derived to describe the dependence of  $F$  on calcium concentration ( $[Ca]$ ):

$$F = [Ca]/(K_{diss} + [Ca])(\alpha_N - \beta_N \log([Ca])) + K_{diss}/(K_{diss} + [Ca])(\alpha_U - \beta_U \log([Ca]))$$

where  $\alpha_N$  is the fluorescence of the native (folded) form of the enzyme,  $\beta_N$  is the linear dependence of  $\alpha_N$  on the logarithm of the calcium concentration (as observed experimentally),  $\alpha_U$  is the fluorescence of the unfolded form and  $\beta_U$  is the linear dependence of  $\alpha_U$  on the logarithm of the calcium concentration.  $K_{diss}$  is the apparent calcium-binding constant for an equilibrium process as follows:



In fact, unfolding proceeds extremely slowly and is irreversible. The rate of unfolding is dependent on calcium concentration, and the dependency for a given  $\alpha$ -amylase provides a measure of the Ca-binding affinity of the enzyme. By defining a standard set of reaction conditions (e.g. 22 hours at 55°C), a meaningful

comparison of  $K_{\text{diss}}$  for different  $\alpha$ -amylases can be made. The calcium dissociation curves for  $\alpha$ -amylases in general can be fitted to the equation above, allowing determination of the corresponding values of  $K_{\text{diss}}$ .

The following values for  $K_{\text{diss}}$  were obtained for the parent  $\alpha$ -amylases having the 5 amino acid sequences shown in SEQ ID No. 1 and SEQ ID No. 2, and for the indicated  $\alpha$ -amylase variants according to the invention (the parent  $\alpha$ -amylase being indicated in parentheses):

Variant	$K_{\text{diss}}$ (mol/l)
10	
D183* + G184* (SEQ ID No. 2)	$1.2 (\pm 0.5) \times 10^{-4}$
L351C + M430C + T183* + G184* (SEQ ID No. 1)	$1.7 (\pm 0.5) \times 10^{-3}$
T183* + G184* (SEQ ID No. 1)	$4.3 (\pm 0.7) \times 10^{-3}$
15 SEQ ID No. 2 (parent)	$4.2 (\pm 1.2) \times 10^{-2}$
SEQ ID No. 1 (parent)	$3.5 (\pm 1.1) \times 10^{-1}$

It is apparent from the above that the calcium-binding affinity of the latter  $\alpha$ -amylolytic enzymes decreases in a downward direction through the above table, 20 i.e. that the pairwise deletion variant D183\* + G184\* (SEQ ID No. 2) binds calcium most strongly (i.e. has the lowest calcium dependency) whilst the parent  $\alpha$ -amylase of SEQ ID No. 1 binds calcium least strongly (i.e. has the highest calcium dependency).

**REFERENCES CITED IN THE SPECIFICATION**

Suzuki et al., the Journal of Biological Chemistry, Vol. 264, No. 32, Issue of November 15, pp. 18933-18938 (1989).

Hudson et al., Practical Immunology, Third edition (1989), Blackwell Scientific Publications.

Lipman and Pearson (1985) Science 227, 1435.

Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor, 1989.

S.L. Beaucage and M.H. Caruthers, Tetrahedron Letters 22, 1981, pp. 1859-1869.

10 Matthes et al., The EMBO J. 3, 1984, pp. 801-805.

R.K. Saiki et al., Science 239, 1988, pp. 487-491.

Morinaga et al., 1984, Biotechnology 2, pp. 646-639.

Nelson and Long, Analytical Biochemistry 180, 1989, pp. 147-151.

Hunkapiller et al., 1984, Nature 310, pp. 105-111.

15 R. Higuchi, B. Krummel, and R.K. Saiki (1988). A general method of *in vitro* preparation and specific mutagenesis of DNA fragments: study of protein and DNA interactions. Nucl. Acids Res. 16, pp. 7351-7367.

Dubnau et al., 1971, J. Mol. Biol. 56, pp. 209-221.

Gryczan et al., 1978, J. Bacteriol. 134, pp. 318-329.

S.D. Erlich, 1977, Proc. Natl. Acad. Sci. 74, pp. 1680-1682.

Boel et al., 1990, Biochemistry 29, pp. 6244-6249.

Deng and Nickoloff, 1992, Anal. Biochem. 200, pp. 81-88.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

## (i) APPLICANT:

5 (A) NAME: NOVO NORDISK A/S  
 (B) STREET: Novo Alle  
 (C) CITY: DK-2880 Bagsvaerd  
 (E) COUNTRY: Denmark  
 (F) POSTAL CODE (ZIP): DK-2880  
 (G) TELEPHONE: +45 44 44 88 88  
 10 (H) TELEFAX: +45 44 49 32 56

(ii) TITLE OF INVENTION: AMYLASE VARIANTS

(iii) NUMBER OF SEQUENCES: 7

## (iv) COMPUTER READABLE FORM:

15 (A) MEDIUM TYPE: Floppy disk  
 (B) COMPUTER: IBM PC compatible  
 (C) OPERATING SYSTEM: PC-DOS/MS-DOS  
 (D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)

## (2) INFORMATION FOR SEQ ID NO: 1:

## (i) SEQUENCE CHARACTERISTICS:

20 (A) LENGTH: 485 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

His His Asn Gly Thr Asn Gly Thr Met Met Gln Tyr Phe Glu Trp Tyr  
 1 5 10 15  
 Leu Pro Asn Asp Gly Asn His Trp Asn Arg Leu Arg Asp Asp Ala Ala  
 20 25 30  
 Asn Leu Lys Ser Lys Gly Ile Thr Ala Val Trp Ile Pro Pro Ala Trp  
 35 40 45  
 Lys Gly Thr Ser Gln Asn Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr  
 50 55 60  
 35 Asp Leu Gly Glu Phe Asn Gln Lys Gly Thr Val Arg Thr Lys Tyr Gly  
 65 70 75 80  
 Thr Arg Asn Gln Leu Gln Ala Ala Val Thr Ser Leu Lys Asn Asn Gly  
 85 90 95



Ile Gln Val Tyr Gly Asp Val Val Met Asn His Lys Gly Gly Ala Asp  
 100 105 110  
 Gly Thr Glu Ile Val Asn Ala Val Glu Val Asn Arg Ser Asn Arg Asn  
 115 120 125  
 5 Gln Glu Thr Ser Gly Glu Tyr Ala Ile Glu Ala Trp Thr Lys Phe Asp  
 130 135 140  
 Phe Pro Gly Arg Gly Asn Asn His Ser Ser Phe Lys Trp Arg Trp Tyr  
 145 150 155 160  
 10 His Phe Asp Gly Thr Asp Trp Asp Gln Ser Arg Gln Leu Gln Asn Lys  
 165 170 175  
 Ile Tyr Lys Phe Arg Gly Thr Gly Lys Ala Trp Asp Trp Glu Val Asp  
 180 185 190  
 Thr Glu Asn Gly Asn Tyr Asp Tyr Leu Met Tyr Ala Asp Val Asp Met  
 195 200 205  
 15 Asp His Pro Glu Val Ile His Glu Leu Arg Asn Trp Gly Val Trp Tyr  
 210 215 220  
 Thr Asn Thr Leu Asn Leu Asp Gly Phe Arg Ile Asp Ala Val Lys His  
 225 230 235 240  
 20 Ile Lys Tyr Ser Phe Thr Arg Asp Trp Leu Thr His Val Arg Asn Thr  
 245 250 255  
 Thr Gly Lys Pro Met Phe Ala Val Ala Glu Phe Trp Lys Asn Asp Leu  
 260 265 270  
 Gly Ala Ile Glu Asn Tyr Leu Asn Lys Thr Ser Trp Asn His Ser Val  
 275 280 285  
 25 Phe Asp Val Pro Leu His Tyr Asn Leu Tyr Asn Ala Ser Asn Ser Gly  
 290 295 300  
 Gly Tyr Tyr Asp Met Arg Asn Ile Leu Asn Gly Ser Val Val Gln Lys  
 305 310 315 320  
 30 His Pro Thr His Ala Val Thr Phe Val Asp Asn His Asp Ser Gln Pro  
 325 330 335  
 Gly Glu Ala Leu Glu Ser Phe Val Gln Gln Trp Phe Lys Pro Leu Ala  
 340 345 350  
 Tyr Ala Leu Val Leu Thr Arg Glu Gln Gly Tyr Pro Ser Val Phe Tyr  
 355 360 365  
 35 Gly Asp Tyr Tyr Gly Ile Pro Thr His Gly Val Pro Ala Met Lys Ser  
 370 375 380  
 Lys Ile Asp Pro Leu Leu Gln Ala Arg Gln Thr Phe Ala Tyr Gly Thr  
 385 390 395 400

Gln His Asp Tyr Phe Asp His His Asp Ile Ile Gly Trp Thr Arg Glu  
 405 410 415

Gly Asn Ser Ser His Pro Asn Ser Gly Leu Ala Thr Ile Met Ser Asp  
 420 425 430

5 Gly Pro Gly Gly Asn Lys Trp Met Tyr Val Gly Lys Asn Lys Ala Gly  
 435 440 445

Gln Val Trp Arg Asp Ile Thr Gly Asn Arg Thr Gly Thr Val Thr Ile  
 450 455 460

10 Asn Ala Asp Gly Trp Gly Asn Phe Ser Val Asn Gly Gly Ser Val Ser  
 465 470 475 480

Val Trp Val Lys Gln  
 485

## (2) INFORMATION FOR SEQ ID NO: 2:

- (i) SEQUENCE CHARACTERISTICS:
- 15 (A) LENGTH: 485 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## 20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

His His Asn Gly Thr Asn Gly Thr Met Met Gln Tyr Phe Glu Trp His  
 1 5 10 15

Leu Pro Asn Asp Gly Asn His Trp Asn Arg Leu Arg Asp Asp Ala Ser  
 20 25 30

25 Asn Leu Arg Asn Arg Gly Ile Thr Ala Ile Trp Ile Pro Pro Ala Trp  
 35 40 45

Lys Gly Thr Ser Gln Asn Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr  
 50 55 60

30 Asp Leu Gly Glu Phe Asn Gln Lys Gly Thr Val Arg Thr Lys Tyr Gly  
 65 70 75 80

Thr Arg Ser Gln Leu Glu Ser Ala Ile His Ala Leu Lys Asn Asn Gly  
 85 90 95

Val Gln Val Tyr Gly Asp Val Val Met Asn His Lys Gly Gly Ala Asp  
 100 105 110

35 Ala Thr Glu Asn Val Leu Ala Val Glu Val Asn Pro Asn Asn Arg Asn  
 115 120 125

85

Gln Glu Ile Ser Gly Asp Tyr Thr Ile Glu Ala Trp Thr Lys Phe Asp  
 130 135 140  
 Phe Pro Gly Arg Gly Asn Thr Tyr Ser Asp Phe Lys Trp Arg Trp Tyr  
 145 150 155 160  
 5 His Phe Asp Gly Val Asp Trp Asp Gln Ser Arg Gln Phe Gln Asn Arg  
 165 170 175  
 Ile Tyr Lys Phe Arg Gly Asp Gly Lys Ala Trp Asp Trp Glu Val Asp  
 180 185 190  
 10 Ser Glu Asn Gly Asn Tyr Asp Tyr Leu Met Tyr Ala Asp Val Asp Met  
 195 200 205  
 Asp His Pro Glu Val Val Asn Glu Leu Arg Arg Trp Gly Glu Trp Tyr  
 210 215 220  
 Thr Asn Thr Leu Asn Leu Asp Gly Phe Arg Ile Asp Ala Val Lys His  
 225 230 235 240  
 15 Ile Lys Tyr Ser Phe Thr Arg Asp Trp Leu Thr His Val Arg Asn Ala  
 245 250 255  
 Thr Gly Lys Glu Met Phe Ala Val Ala Glu Phe Trp Lys Asn Asp Leu  
 260 265 270  
 20 Gly Ala Leu Glu Asn Tyr Leu Asn Lys Thr Asn Trp Asn His Ser Val  
 275 280 285  
 Phe Asp Val Pro Leu His Tyr Asn Leu Tyr Asn Ala Ser Asn Ser Gly  
 290 295 300  
 Gly Asn Tyr Asp Met Ala Lys Leu Leu Asn Gly Thr Val Val Gln Lys  
 305 310 315 320  
 25 His Pro Met His Ala Val Thr Phe Val Asp Asn His Asp Ser Gln Pro  
 325 330 335  
 Gly Glu Ser Leu Glu Ser Phe Val Gln Glu Trp Phe Lys Pro Leu Ala  
 340 345 350  
 30 Tyr Ala Leu Ile Leu Thr Arg Glu Gln Gly Tyr Pro Ser Val Phe Tyr  
 355 360 365  
 Gly Asp Tyr Tyr Gly Ile Pro Thr His Ser Val Pro Ala Met Lys Ala  
 370 375 380  
 Lys Ile Asp Pro Ile Leu Glu Ala Arg Gln Asn Phe Ala Tyr Gly Thr  
 385 390 395 400  
 35 Gln His Asp Tyr Phe Asp His His Asn Ile Ile Gly Trp Thr Arg Glu  
 405 410 415  
 Gly Asn Thr Thr His Pro Asn Ser Gly Leu Ala Thr Ile Met Ser Asp  
 420 425 430

Gly Pro Gly Gly Glu Lys Trp Met Tyr Val Gly Gln Asn Lys Ala Gly  
 435 440 445

Gln Val Trp His Asp Ile Thr Gly Asn Lys Pro Gly Thr Val Thr Ile  
 450 455 460

5 Asn Ala Asp Gly Trp Ala Asn Phe Ser Val Asn Gly Gly Ser Val Ser  
 465 470 475 480

Ile Trp Val Lys Arg  
 485

## (2) INFORMATION FOR SEQ ID NO: 3:

- 10 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 514 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

- 15 (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

Ala Ala Pro Phe Asn Gly Thr Met Met Gln Tyr Phe Glu Trp Tyr Leu  
 1 5 10 15

Pro Asp Asp Gly Thr Leu Trp Thr Lys Val Ala Asn Glu Ala Asn Asn  
 20 20 25 30

Leu Ser Ser Leu Gly Ile Thr Ala Leu Trp Leu Pro Pro Ala Tyr Lys  
 35 40 45

Gly Thr Ser Arg Ser Asp Val Gly Tyr Gly Val Tyr Asp Leu Tyr Asp  
 50 55 60

25 Leu Gly Glu Phe Asn Gln Lys Gly Ala Val Arg Thr Lys Tyr Gly Thr  
 65 70 75 80

Lys Ala Gln Tyr Leu Gln Ala Ile Gln Ala Ala His Ala Ala Gly Met  
 85 90 95

30 Gln Val Tyr Ala Asp Val Val Phe Asp His Lys Gly Gly Ala Asp Gly  
 100 105 110

Thr Glu Trp Val Asp Ala Val Glu Val Asn Pro Ser Asp Arg Asn Gln  
 115 120 125

Glu Ile Ser Gly Thr Tyr Gln Ile Gln Ala Trp Thr Lys Phe Asp Phe  
 130 135 140

35 Pro Gly Arg Gly Asn Thr Tyr Ser Ser Phe Lys Trp Arg Trp Tyr His  
 145 150 155 160

Phe Asp Gly Val Asp Trp Asp Glu Ser Arg Lys Leu Ser Arg Ile Tyr  
 165 170 175  
 Lys Phe Arg Gly Ile Gly Lys Ala Trp Asp Trp Glu Val Asp Thr Glu  
 180 185 190  
 5 Asn Gly Asn Tyr Asp Tyr Leu Met Tyr Ala Asp Leu Asp Met Asp His  
 195 200 205  
 Pro Glu Val Val Thr Glu Leu Lys Ser Trp Gly Lys Trp Tyr Val Asn  
 210 215 220  
 10 Thr Thr Asn Ile Asp Gly Phe Arg Leu Asp Ala Val Lys His Ile Lys  
 225 230 235 240  
 Phe Ser Phe Phe Pro Asp Trp Leu Ser Asp Val Arg Ser Gln Thr Gly  
 245 250 255  
 Lys Pro Leu Phe Thr Val Gly Glu Tyr Trp Ser Tyr Asp Ile Asn Lys  
 260 265 270  
 15 Leu His Asn Tyr Ile Met Lys Thr Asn Gly Thr Met Ser Leu Phe Asp  
 275 280 285  
 Ala Pro Leu His Asn Lys Phe Tyr Thr Ala Ser Lys Ser Gly Gly Thr  
 290 295 300  
 20 Phe Asp Met Arg Thr Leu Met Thr Asn Thr Leu Met Lys Asp Gln Pro  
 305 310 315 320  
 Thr Leu Ala Val Thr Phe Val Asp Asn His Asp Thr Glu Pro Gly Gln  
 325 330 335  
 Ala Leu Gln Ser Trp Val Asp Pro Trp Phe Lys Pro Leu Ala Tyr Ala  
 340 345 350  
 25 Phe Ile Leu Thr Arg Gln Glu Gly Tyr Pro Cys Val Phe Tyr Gly Asp  
 355 360 365  
 Tyr Tyr Gly Ile Pro Gln Tyr Asn Ile Pro Ser Leu Lys Ser Lys Ile  
 370 375 380  
 30 Asp Pro Leu Leu Ile Ala Arg Arg Asp Tyr Ala Tyr Gly Thr Gln His  
 385 390 395 400  
 Asp Tyr Leu Asp His Ser Asp Ile Ile Gly Trp Thr Arg Glu Gly Val  
 405 410 415  
 Thr Glu Lys Pro Gly Ser Gly Leu Ala Ala Leu Ile Thr Asp Gly Pro  
 420 425 430  
 35 Gly Gly Ser Lys Trp Met Tyr Val Gly Lys Gln His Ala Gly Lys Val  
 435 440 445  
 Phe Tyr Asp Leu Thr Gly Asn Arg Ser Asp Thr Val Thr Ile Asn Ser  
 450 455 460

Asp Gly Trp Gly Glu Phe Lys Val Asn Gly Gly Ser Val Ser Val Trp  
 465 470 475 480  
 Val Pro Arg Lys Thr Thr Val Ser Thr Ile Ala Trp Ser Ile Thr Thr  
 485 490 495  
 5 Arg Pro Trp Thr Asp Glu Phe Val Arg Trp Thr Glu Pro Arg Leu Val  
 500 505 510  
 Ala Trp

## (2) INFORMATION FOR SEQ ID NO: 4:

- 10 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 1455 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear  
 15 (ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

CATCATAATG GAACAAATGG TACTATGATG CAATATTTTG AATGGTATTT GCCAAATGAC 60  
 GGGATCAATT GGAACAGGTT GAGGGATGAC GCAGCTAACT TAAAGAGTAA AGGGATAACA 120  
 GCTGTATGGA TOCCACCTGC ATGGAAGGGG ACTTCCCAGA ATGATGTAGG TTATGGAGCC 180  
 20 TATGATTTAT ATGATCTTGG AGAGTTTAAC CAGAAGGGGA CGTTTGTAC AAAATATGGA 240  
 ACACGCAACC AGCTACAGGC TCGGGTGACC TCTTTAAAAA ATAACGGCAT TCAGGTATAT 300  
 GGTGATGTGC TCATGAATCA TAAAGGTGGA GCAGATGGTA CGGAAATTGT AAATGCGGTA 360  
 GAAGTGAATC GGAGCAACCG AAACCAGGAA ACCTCAGGAG AGTATGCAAT AGAAGCGTGG 420  
 ACAAAGTTTG ATTTTCTCTG AAGAGGAAAT AACCATTCCA GCTTTAAGTG GCGCTGGTAT 480  
 25 CATTTTGATG GGACAGATTG GGATCAGTCA CGCCAGCTTC AAAACAAAAT ATATAAATTC 540  
 AGGGGAACAG GCAAGGCCTG GGA CTGGGAA GTGATACAG AGAATGGCAA CTATGACTAT 600  
 CTTATGTATG CAGACGTGGA TATGGATCAC CCAGAAGTAA TACATGAACT TAGAACTGG 660  
 GGAGTGTGGT ATACGAATAC ACTGAACCTT GATGGATTTA GAATAGATGC AGTGAAACAT 720  
 ATAAAATATA GCTTTACGAG AGATTGGCTT ACACATGTGC GTAACACCAC AGGTAAACCA 780  
 30 ATGTTTGCAG TGGCTGAGTT TTGGAAAAAT GACCTTGGTG CAATTGAAAA CTATTTGAAT 840  
 AAAACAAGTT GGAATCACTC GGTGTTTGAT GTTCCCTCC ACTATAATTT GTACAATGCA 900

TCTAATAGCG GTGGTTATTA TGATATGAGA AATATTTTAA ATGGTTCGTG GTTGCAAAAA 960  
 CATCCAACAC ATGCCGTTAC TTTTGTGTAT AACCATGATT CTCAGCCCGG GGAAGCATTG 1020  
 GAATCCTTTG TTCAACAATG GTTTAAACCA CTTCATATG CATTGGTTCT GACAAGGGAA 1080  
 CAAGTTATC CTTCGTATT TTATGGGAT TACTACGGTA TCCCAACCA TGGTGTCCG 1140  
 5 GCTATGAAAT CTAAATAGA CCTCTCTCG CAGGCACGTC AAACTTTTCG CTATGGTACG 1200  
 CAGCATGATT ACTTTGATCA TCATGATATT ATCGGTGGA CAAGAGAGG AAATAGCTCC 1260  
 CATCCAAAT CAGGCCTTGC CACCATTATG TCAGATGGTC CAGGTGGTAA CAAATGGATG 1320  
 TATGTGGGGA AAAATAAAGC GGGACAAGT TGGAGAGATA TTACCGGAA TAGGACAGGC 1380  
 ACGTCACAA TTAATGCAGA CGGATGGGGT AATTTCTCTG TTAATGGAGG GTCGGTTTCG 1440  
 10 GTTTGGGIGA AGCAA 1455

## (2) INFORMATION FOR SEQ ID NO: 5:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1455 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

CATCATAATG GGACAAATGG GACGATGATG CAATACCTTG AATGGCACTT GCCTAATGAT 60  
 20 GGGAACTACT GGAATAGATT AAGAGATGAT GCTAGTAATC TAAGAAATAG AGGTATAACC 120  
 GCTATTTGGA TTCCGCTGCT CTGGAAAGGG ACTTCGCAA ATGATGTGGG GTATGGAGCC 180  
 TATGATCTTT ATGATTTAGG GGAATTTAAT CAAAAGGGGA CGGTTCGTAC TAAGTATGGG 240  
 ACACGTAGTC AATTGGAGTC TGCCATCCAT GCTTTAAAGA ATAATGGCGT TCAAGTTTAT 300  
 GGGATGTAG TGATGAACCA TAAAGGAGGA GCTGATGCTA CAGAAAACGT TCTTCCTGTC 360  
 25 GAGGTGAATC CAAATAACCG GAATCAAGAA ATATCTGGGG ACTACACAAT TGAGGCTTGG 420  
 ACTAAGTTTG ATTTTCAGG GAGGGTAAAT ACATACTCAG ACTTTAAATG GCGTTGGTAT 480  
 CATTTCGATG GTGTAGATTG GGATCAATCA CGACAATTC AAAATCGTAT CTACAAATTC 540  
 CGAGGTGATG GTAAGGCATG GGATGGGAA GTAGATTCGG AAAATGGAAA TTATGATTAT 600  
 TTAATGTATG CAGATGTACA TATGGATCAT CCGAGGTAG TAAATGAGCT TAGAAGATGG 660

GGAGAATGGT ATACAAATAC ATTAAATCTT GATGGATTTA GGATOGATGC GGTGAAGCAT 720  
 ATTAAATATA GCTTTACACG TGATTGGTTG ACCCATGTAA GAAACGCAAC GGGAAAAGAA 780  
 AIGTTTGCTG TIGCTGAATT TTGGAAAAT GATTTAGGTG CCTTGGAGAA CTATTTAAAT 840  
 AAAACAAACT GGAATCAATC TGTCTTTGAT GTCCCCCTTC ATTATAATCT TTATAACGGC 900  
 5 TCAAAATAGTG GAGGCAACTA TGACATGGCA AAACCTCTTA ATGGAACGGT TGTTCAAAAG 960  
 CATCCAATGC ATGCOGTAACT TTTTGTGGAT AATCAGGATT CTCAACCTGG GGAATCATT 1020  
 GAATCATTTG TACAAGAATG GTTTAAGCCA CTTCCTTATG CGCTTATTTT AACAGAGAA 1080  
 CAAGGCTATC CCTCTGTCTT CTATGGTGAC TACTATGGAA TTCCAACACA TAGTGTCCCA 1140  
 GCAATGAAAG CCAAGATTGA TOCAATCTTA GAGGCGGTC AAAATTTTGC ATATGGAACA 1200  
 10 CAACATGATT ATTTTGACCA TCATAATATA ATCGGATGGA CACGTGAAGG AAATACCACG 1260  
 CATCCCAATT CAGGACTTGC GACTATCATG TOGGATGGG CAGGGGGAGA GAAATGGATG 1320  
 TACGTAGGGC AAAATAAAGC AGGTCAAGTT TGGCATGACA TAACTGGAAA TAAACCAGGA 1380  
 ACAGTTACGA TCAATGCAGA TGGATGGGCT AATTTTTCAG TAAATGGAGG ATCTGTTTCC 1440  
 ATTTGGGTGA AACGA 1455

15 (2) INFORMATION FOR SEQ ID NO: 6:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1548 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

20

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

GCGCACCGT TTAACGGCAC CATGATGCAG TATTTTGAAT GGTACTTGCC GGATGATGGC 60  
 ACGTTATGGA CCAAGTGGC CAATGAAGCC AACAACTTAT CCAGCCTTGG CATCACCGCT 120  
 25 CTTTGGCTGC CGCCCGCTTA CAAAGGAACA AGCCGCAGCG ACGTAGGGTA CGGAGTATAC 180  
 GACTTGATG ACCTGGCGA ATTCAATCAA AAAGGGACCG TCCGACAAA ATACGGAACA 240  
 AAAGCTCAAT ATCTTCAAGC CATTCAAGCC GCCCAGCCG CTGGAATGCA AGTGTACGCC 300  
 GATGTCGTGT TCGACCATAA AGGCGGCGCT GACGCGACGG AATGGGTGGA CGCCGTGAA 360  
 GTCAATCCGT CCGACGCAA CCAAGAAATC TCGGCACCT ATCAAAATCCA AGCATGGACG 420



AAATTGATT TTCCCGGGCG GGGCAACACC TACTCCAGCT TTAAGTGGCG CTGGIACCAT 480  
 TTTGACGGCG TTGATTGGGA CGAAAGCCGA AAATTGAGCC GCATTITACAA ATTCCGCGGC 540  
 ATCGGCAAAG CGTGGGATTG GGAAGTAGAC ACGGAAAACG GAAACTATGA CTACTTAATG 600  
 TATGCGGACC TTGATATGGA TCATCCCGAA GTCGTGACCG AGCTGAAAAA CTGGGGGAAA 660  
 5 TGGTATGTCA ACACAACGAA CATTGATGGG TTCCGGCTTG ATGCCGTCAA GCATATTAAG 720  
 TTCAGTTTTT TTCTGATTG GTTGTGTAT GTTCGTTCTC AGACTGGCAA GCGCTATTT 780  
 ACCGTGGGG AATATTGGAG CTATGACATC AACAGTTGC ACAATTACAT TACGAAAACA 840  
 GACGGAACGA TGTCTTGTG TGATGCCCCG TTACACAACA AATTTTATAC CGCTTCCAAA 900  
 TCAGGGGGCG CATTGATAT GCGCAGTTA ATGACCAATA CTCTCATGAA AGATCAACCG 960  
 10 ACATTGGCCG TCACCTTGT TGATAATCAT GACACCGAAC CCGGCCAAGC GCTGCAGTCA 1020  
 TGGGTGACC CATGGTCAA ACCGTGGCT TACGCCTTA TTCTAACTG GCAGGAAGGA 1080  
 TACCGTGGCG TCTTTATGG TGAATATTAT GGCATTCCAC AATATAACAT TCCTTCGCTG 1140  
 AAAAGCAAAA TCGATCCGCT CCTCATCGCG CGCAGGGATT ATGCTTACCG AACGCAACAT 1200  
 GATTATCTTG ATCACTCCGA CATCATCGGG TGGACAAGGG AAGGGGGCAC TGAAAAACCA 1260  
 15 GGATCCGGAC TGGCCGCACT GATCAACGAT GGGCCGGGAG GAAGCAAATG GATGTACGTT 1320  
 GGCAAACAAC ACGCTGGAAA AGTGTCTAT GACCTTACCG GCAACCGGAG TGACACCGTC 1380  
 ACCATCAACA GTGATGGATG GGGGAATTC AAAGTCAATG GCGGTTGGT TTCGGTTTGG 1440  
 GTTCCTAGAA AAACGACCGT TTCTACCATC GCTCGGCCGA TCACAACCG ACCGTGGACT 1500  
 GGTGAATTG TCGTTGGAC CGAACCACCG TTGGTGGCAT GGCCTTGA 1548

20 (2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 485 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

25

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

His His Asn Gly Thr Asn Gly Thr Met Met Gln Tyr Phe Glu Trp Tyr  
 1 5 10 15

Leu Pro Asn Asp Gly Asn His Trp Asn Arg Leu Asn Ser Asp Ala Ser  
 20 25 30  
 Asn Leu Lys Ser Lys Gly Ile Thr Ala Val Trp Ile Pro Pro Ala Trp  
 35 40 45  
 5 Lys Gly Ala Ser Gln Asn Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr  
 50 55 60  
 Asp Leu Gly Glu Phe Asn Gln Lys Gly Thr Val Arg Thr Lys Tyr Gly  
 65 70 75 80  
 10 Thr Arg Ser Gln Leu Gln Ala Ala Val Thr Ser Leu Lys Asn Asn Gly  
 85 90 95  
 Ile Gln Val Tyr Gly Asp Val Val Met Asn His Lys Gly Gly Ala Asp  
 100 105 110  
 Ala Thr Glu Met Val Arg Ala Val Glu Val Asn Pro Asn Asn Arg Asn  
 115 120 125  
 15 Gln Glu Val Thr Gly Glu Tyr Thr Ile Glu Ala Trp Thr Arg Phe Asp  
 130 135 140  
 Phe Pro Gly Arg Gly Asn Thr His Ser Ser Phe Lys Trp Arg Trp Tyr  
 145 150 155 160  
 20 His Phe Asp Gly Val Asp Trp Asp Gln Ser Arg Arg Leu Asn Asn Arg  
 165 170 175  
 Ile Tyr Lys Phe Arg Gly His Gly Lys Ala Trp Asp Trp Glu Val Asp  
 180 185 190  
 Thr Glu Asn Gly Asn Tyr Asp Tyr Leu Met Tyr Ala Asp Ile Asp Met  
 195 200 205  
 25 Asp His Pro Glu Val Val Asn Glu Leu Arg Asn Trp Gly Val Trp Tyr  
 210 215 220  
 Thr Asn Thr Leu Gly Leu Asp Gly Phe Arg Ile Asp Ala Val Lys His  
 225 230 235 240  
 30 Ile Lys Tyr Ser Phe Thr Arg Asp Trp Ile Asn His Val Arg Ser Ala  
 245 250 255  
 Thr Gly Lys Asn Met Phe Ala Val Ala Glu Phe Trp Lys Asn Asp Leu  
 260 265 270  
 Gly Ala Ile Glu Asn Tyr Leu Gln Lys Thr Asn Trp Asn His Ser Val  
 275 280 285  
 35 Phe Asp Val Pro Leu His Tyr Asn Leu Tyr Asn Ala Ser Lys Ser Gly  
 290 295 300  
 Gly Asn Tyr Asp Met Arg Asn Ile Phe Asn Gly Thr Val Val Gln Arg  
 305 310 315 320

His Pro Ser His Ala Val Thr Phe Val Asp Asn His Asp Ser Gln Pro  
 325 330 335  
 Glu Glu Ala Leu Glu Ser Phe Val Glu Glu Trp Phe Lys Pro Leu Ala  
 340 345 350  
 5 Tyr Ala Leu Thr Leu Thr Arg Glu Gln Gly Tyr Pro Ser Val Phe Tyr  
 355 360 365  
 Gly Asp Tyr Tyr Gly Ile Pro Thr His Gly Val Pro Ala Met Arg Ser  
 370 375 380  
 10 Lys Ile Asp Pro Ile Leu Glu Ala Arg Gln Lys Tyr Ala Tyr Gly Lys  
 385 390 395 400  
 Gln Asn Asp Tyr Leu Asp His His Asn Ile Ile Gly Trp Thr Arg Glu  
 405 410 415  
 Gly Asn Thr Ala His Pro Asn Ser Gly Leu Ala Thr Ile Met Ser Asp  
 420 425 430  
 15 Gly Ala Gly Gly Ser Lys Trp Met Phe Val Gly Arg Asn Lys Ala Gly  
 435 440 445  
 Gln Val Trp Ser Asp Ile Thr Gly Asn Arg Thr Gly Thr Val Thr Ile  
 450 455 460  
 20 Asn Ala Asp Gly Trp Gly Asn Phe Ser Val Asn Gly Gly Ser Val Ser  
 465 470 475 480  
 Ile Trp Val Asn Lys  
 485

**CLAIMS**

1. A variant of a parent  $\alpha$ -amylase, which parent  $\alpha$ -amylase (i) has an amino acid sequence selected from the amino acid sequences shown in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, and SEQ ID No. 7, respectively; or (ii) displays at least 5 80% homology with one or more of said amino acid sequences; and/or displays immunological cross-reactivity with an antibody raised against an  $\alpha$ -amylase having one of said amino acid sequences; and/or is encoded by a DNA sequence which hybridizes with the same probe as a DNA sequence encoding an  $\alpha$ -amylase having one of said amino acid sequences; in which variant:
- 10 (a) at least one amino acid residue of said parent  $\alpha$ -amylase has been deleted; and/or
- (b) at least one amino acid residue of said parent  $\alpha$ -amylase has been replaced by a different amino acid residue; and/or
- (c) at least one amino acid residue has been inserted relative to said parent 15  $\alpha$ -amylase;
- said variant having  $\alpha$ -amylase activity and exhibiting at least one of the following properties relative to said parent  $\alpha$ -amylase: increased thermostability; increased stability towards oxidation; and reduced  $\text{Ca}^{2+}$  dependency;
- with the proviso that the amino acid sequence of said variant is not identical to any 20 of the amino acid sequences shown in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 and SEQ ID No. 7, respectively.
2. A variant according to claim 1, wherein at least one oxidizable amino acid residue of said parent  $\alpha$ -amylase has been deleted or has been replaced by a different amino acid residue which is less susceptible to oxidation than said oxidizable amino 25 acid residue.
3. A variant according to claim 2, wherein said oxidizable amino acid residue is selected from the group consisting of methionine, tryptophan, cysteine and tyrosine.

4. A variant according to claim 2 or 3, wherein said oxidizable amino acid residue is a methionine which is, or which is equivalent to, M9, M10, M105, M202, M208, M261, M309, M382, M430 or M440 of the amino acid sequence shown in SEQ ID No. 1.
- 5 5. A variant according to claim 4, comprising a methionine substitution which is, or which is equivalent to, one of the following substitutions in the amino acid sequence shown in SEQ ID No. 1: M9L; M10L; M105L; M202L,T,F,I,V; M208L; M261L; M309L; M382L; M430L; M440L.
6. A variant according to any one of claims 3-5, wherein a said methionine residue  
10 has been replaced by threonine.
7. A variant according to any one of the preceding claims, wherein at least one amino acid which is, or which is equivalent to, F180, R181, G182, T183, G184 or K185 of the amino acid sequence shown in SEQ ID No. 1 has been deleted.
8. A variant according to claim 7, wherein the deleted amino acids are, or are  
15 equivalent to, any two of said amino acid residues.
9. A variant according to claim 8, wherein the deletions are, or are equivalent to, R181\* + G182\*; or T183\* + G184\*.
10. A variant according to any one of the preceding claims, comprising an amino acid substitution which is, or which is equivalent to, one of the following  
20 substitutions in the amino acid sequence shown in SEQ ID No. 1: K269R; P260E; R124P; M105F,I,L,V; M208F,W,Y; L217I; V206I,L,F.
11. A variant according to any one of the preceding claims, comprising an amino acid substitution which is, or which is equivalent to, one of the following substitutions in the amino acid sequence shown in SEQ ID No. 1: Y243F; K108R;

K179R; K239R; K242R; K269R; D163N; D188N; D192N; D199N; D205N; D207N; D209N; E190Q; E194Q; N106D.

12. A DNA construct comprising a DNA sequence encoding an  $\alpha$ -amylase variant according to any one of claims 1-11.

5 13. A recombinant expression vector which carries a DNA construct according to claim 12.

14. A cell which is transformed with a DNA construct according to claim 12 or a vector according to claim 13.

15. A cell according to claim 14, which is a microorganism.

10 16. A cell according to claim 15, which is a bacterium or a fungus.

17. A cell according to claim 16, which is a grampositive bacterium such as *Bacillus subtilis*, *Bacillus licheniformis*, *Bacillus lentus*, *Bacillus brevis*, *Bacillus stearothermophilus*, *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus coagulans*, *Bacillus circulans*, *Bacillus lautus*, *Bacillus thuringiensis* or *Streptomyces lividans*  
15 or *Streptomyces murinus*, or a gramnegative bacterium such as *E.coli*.

18. A method of producing an  $\alpha$ -amylase variant according to any one of claims 1-11, wherein a cell according to any one of claims 14-17 is cultured under conditions conducive to the production of the  $\alpha$ -amylase variant, and the  $\alpha$ -amylase variant is subsequently recovered from the culture.

20 19. Use of an  $\alpha$ -amylase variant according to any one of claims 1-11 for washing and/or dishwashing.

20. A detergent additive comprising an  $\alpha$ -amylase variant according to any one of claims 1-11, optionally in the form of a non-dusting granulate, stabilised liquid or protected enzyme.
21. A detergent additive according to claim 20, comprising 0.02-200 mg of enzyme  
5 protein per gram of the additive.
22. A detergent additive according to claim 20 or 21, which additionally comprises another enzyme such as a protease, a lipase, a peroxidase, another amylolytic enzyme and/or a cellulase.
23. A detergent composition comprising an  $\alpha$ -amylase variant according to any one  
10 of claims 1-11, and a surfactant.
24. A detergent composition according to claim 23, which additionally comprises another enzyme such as a protease, a lipase, a peroxidase, another amylolytic enzyme and/or a cellulase.
25. A manual or automatic dishwashing detergent composition comprising an  
15  $\alpha$ -amylase variant according to any one of claims 1-11, and a surfactant.
26. A dishwashing detergent composition according to claim 25, which additionally comprises another enzyme such as a protease, a lipase, a peroxidase, another amylolytic enzyme and/or a cellulase.
27. A manual or automatic laundry washing composition comprising an  $\alpha$ -amylase  
20 variant according to any one of claims 1-11, and a surfactant.
28. A laundry washing composition according to claim 27, which additionally comprises another enzyme such as a protease, a lipase, a peroxidase, an amylolytic enzyme and/or a cellulase.

29. Use of an  $\alpha$ -amylase variant according to any one of claims 1-11 for textile desizing.



1/5

	10	20	30	40	50	60	
1	HHNGTNGTMMQYFEWYLPNDGNHWNRLRDDAANLKS	KGITAVWI	PPAWKGTSQNDVGYGA			60	
3	-AAPFNGTMMQYFEWYLPDDGTLWTKVANEANNLSSLG	ITALWLPP	AYKGTSRSDVGYGV			59	
2	HHNGTNGTMMQYFEWHL PNDGNHWNRLRDDASNLNR	GITAIWI	PPAWKGTSQNDVGYGA			60	
4	HHNGTNGTMMQYFEWYLPNDGNHWNRLNSDASNLKS	KGITAVWI	PPAWKGASQNDVGYGA			60	
	70	80	90	100	110	120	
1	YDLYDLGEFNQKGTVRTKYGTRNQLQAAVTSLKNNG	IQVYGDVVMNHKGGADGTEIVNAV				120	
3	YDLYDLGEFNQKGTVRTKYGTAKQYLQAIQAAHAAGM	QVYADVVDHKG	GADGTEWVDAV			119	
2	YDLYDLGEFNQKGTVRTKYGTRSQLESIAHALKNNG	VQVYGDVVMNHKGGADATENVLAV				120	
4	YDLYDLGEFNQKGTVRTKYGTRSQQAQAVTSLKNNG	IQVYGDVVMNHKGGADATEMVRVAV				120	
	130	140	150	160	170	180	
1	EVNRSNRNQETSGEYAI EAWTKFDFPGRGNHSSFK	KWRWYHFDGTDWDQSRQLQNKIYKF				180	
3	EVNPSDRNQEISGTYQIQAWTKFDFPGRGNTYSSFK	KWRWYHFDGVDWDESRKLS-RIYKF				178	
2	EVNPNNRNQEISGTYTIEAWTKFDFPGRGNTYSDF	KWRWYHFDGVDWDQSRQFQNR IYKF				180	
4	EVNPNNRNQEVTGEYTI EAWTRFDFPGRGNTHSS	FKWRWYHFDGVDWDQSRRLNRIYKF				180	
	190	200	210	220	230	240	
1	RGTGKAWDWEVDTEGNYDYL MYADVMDHPEVIHEL	RNWGVWYTNTLNLDGFRIDAVKH				240	
3	RGIGKAWDWEVDTEGNYDYL MYADLMDHPEVVTEL	KNWGKQVYVNTNIDGFRIDAVKH				238	
2	RGDGKAWDWEVDSENGNYDYL MYADVMDHPEVVNEL	RRWGEWYTNTLNLDGFRIDAVKH				240	
4	RGHGKAWDWEVDTEGNYDYL MYADIDMDHPEVVNEL	RNWGVWYTNTLGLDGFRIDAVKH				240	
	250	260	270	280	290	300	
1	IKYSFTRDWLTHVRNTTGKPMFAVAEFWKNDLGA	IENYLNKTSWNHSAFDVPLHYNLYNA				300	
3	IKFSFFPDWLSYVRSQTGKPLFTVGEYWSYDINKL	HNYITKTGDTMSLFDAPLHNKFYTA				298	
2	IKYSFTRDWLTHVRNATGKEMFAVAEFWKNDLGA	LENYLNKTNWNHSAFVFDVPLHYNLYNA				300	
4	IKYSFTRDWINHVRSATGKNMFAVAEFWKNDLGA	IENYLQKTNNHSAFVFDVPLHYNLYNA				300	
	310	320	330	340	350	360	
1	SNSGGYYDMRNILNGSVVQKHPHVAFTFVDNHDS	QPGEALESFVQQWFKPLAYALVLTRE				360	
3	SKSGGAFDMRMLMTNTLMKDQPTLAVTFVDNHDT	EPGQALQSWVDPWFKPLAYAFILTRO				358	
2	SNSGGNYDMAKLLNGTVVQKHPHVAFTFVDNHDS	QPGESLESFVQEWFKPLAYALILTRE				360	
4	SKSGGNYDMRNIFNGTVVQRHPSHAVTFVDNHDS	QPEEALESFVEEWFKPLAYALTLTRE				360	
	370	380	390	400	410	420	
1	QGYPVSVFYGDYYGIPTHGVPAMKSKIDPLLQARQT	FAYGTQHDYFDHHDIIIGWTREGNSS				420	
3	EGYPCVFYGDYYGIPQYNIPLSKSKIDPLLIARRDY	AYGTQHDYLDHSDIIIGWTREGGTE				418	
2	QGYPVSVFYGDYYGIPTHSVPMKAKIDPILEARQNF	AYGTQHDYFDHHDIIIGWTREGNTT				420	
4	QGYPVSVFYGDYYGIPTHGVPAMRSKIDPILEARQ	KYAYGKQNDYLDHHDIIIGWTREGNTA				420	
	430	440	450	460	470	480	
1	HPNSGLATIMSDGPGGNKWMYVGKQKAGQVWRD	ITGNRTGTVTINADGWGNFSVNGGSVS				480	
3	KPGSGLAALITDGPGGSKWMYVGKQKAGQVYD	LTGNRSDTVTINSDGWGEFKVNGGSVS				478	
2	HPNSGLATIMSDGPGGEKWMYVGQNKAGQVWHD	ITGNKPGTVTINADGWANFSVNGGSVS				480	
4	HPNSGLATIMSDGAGGSKWMFVGRNKAQVWSD	ITGNRTGTVTINADGWGNFSVNGGSVS				480	
	490	500	510	520	530	540	
1	VWVKQ					485	
3	VWVPRKTTVSTIARPITTRPWTGEFVRWTEPRLVAV					514	
2	IWVKR					485	
4	IWVNK					485	

Fig. 1

SUBSTITUTE SHEET (RULE 26)

2/5




Fig. 2

3/5




Fig. 3

4/5




Fig. 4

5/5




Fig. 5

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 96/00056

## A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C12N 9/28 // C11D 3/386

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CA, WPI, EMBL/GEN BANK/DDBJ

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 9510603 A1 (NOVO NORDISK A/S), 20 April 1995 (20.04.95), abstract --	1-6,12-29
P,X	WO 9521247 A1 (NOVO NORDISK A/S), 10 August 1995 (10.08.95), claim 2 --	1-6,12-29
P,X	WO 9526397 A1 (NOVO NORDISK A/S), 5 October 1995 (05.10.95) --	1-6,12-29
X	WO 9402597 A1 (NOVO NORDISK A/S), 3 February 1994 (03.02.94), claim 5, abstract --	1-6,12-29

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*&\* document member of the same patent family

Date of the actual completion of the international search

12 June 1996

Date of mailing of the international search report

18 -06- 1996

Name and mailing address of the ISA/  
Swedish Patent Office  
Box 5055, S-102 42 STOCKHOLM  
Facsimile No. +46 8 666 02 86

Authorized officer

Yvonne Siösteen  
Telephone No. +46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 96/00056

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9116423 A1 (NOVO NORDISK A/S), 31 October 1991 (31.10.91), claims 11,12 --	1-6,12-29
X	WO 9418314 A1 (GENENCOR INTERNATIONAL, INC.), 18 August 1994 (18.08.94), see the claims --	1-6,12-29
A	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Volume 151, No 1, February 1988, Akira Tsukamoto et al, "Nucleotide sequence of the maltohexaose-producing amylase gene from an alkalophilic bacillus sp. 707 and structural similarity to liquefying type alpha-amylases" page 25 - page 31 --	1-6,12,29
A	THE JOURNAL OF BIOLOGICAL CHEMISTRY, Volume 260, No 11, June 1985, David A. Estell et al, "Engineering an Enzyme by Sitedirected Mutagenesis to Be Resistant to Chemical Oxidation" page 6518 - page 6521 --	1-6,12-29
X	WO 9100353 A2 (GIST-BROCADES N.V.ET AL), 10 January 1991 (10.01.91), page 19, line 33 - line 34, claims --	1,7-10,12-29
X	FR 2676456 A1 (INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE), 20 November 1992 (20.11.92) --	1,7-10,12-29
X	FR 2665178 A1 (INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE), 31 January 1992 (31.01.92) --	1,7-10,12-29

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 96/00056

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Dialog Information Services, File 351, DERWENT WPI, Dialog accession no. 007176688, WPI, accession no. 87-173697/25, (HIGETA SHOYU KK), "DNA expressing highly-thermostable enzyme formed by adding one more cysteine codon in structural gene", & JP,A,62104580, 870515, 8725 (Basic)  --	1,7-10,12-29
A	THE JOURNAL OF BIOLOGICAL CHEMISTRY, Volume 264, No 32, November 1989, Suzuki et al, "Amino Acid Residues Stabilizing a Bacillus alfa-Amylase against Irreversible Theroinactivation", page 18933 - page 18938  --	1,7-10,12-29
P,X	WO 9535382 A2 (GISTBROCADES B.V.), 28 December 1995 (28.12.95), claims 1-2  --	1,11
X	Chemical Abstracts, Volume 112, No 15, 9 April 1990 (09.04.90), (Columbus, Ohio, USA), Vihinen, Mauno et al, "Site-directed mutagenesis of a thermostable alfa-amylase from Bacillus stearothermophilus", page 347, THE ABSTRACT No 135178r, J. Biochem. 1990, 107 (2), 267-272  --	1,11
A	Chemical Abstracts, Volume 108, No 11, 14 March 1988 (14.03.88), (Columbus, Ohio, USA), Buisson, G. et al, "Three dimensional structure of porcine pancreatic alfa-amylase at 2.9 Å resolution. Role of calcium in structure and activity", page 325, THE ABSTRACT No 90927h, EMBO J. 1987, 6 (13), 3909-3916  --	1,11
A	Chemical Abstracts, Volume 112, No 19, 7 May 1990 (07.05.90), (Columbus, Ohio, USA), Holm, Liisa et al, "Random mutagenesis used to probe the structure and function of Bacillus stearothermophilus alpha-amylase", page 351, THE ABSTRACT No 174785f, Protein Eng. 1990, 3 (3), 181-191  --	1-29



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 96/00056

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4600693 A (KINDLE ET AL), 15 July 1986 (15.07.86), abstract  --	1-11
A	WO 8700202 A1 (NUTRASWEET COMPANY), 15 January 1987 (15.01.87)  -- -----	1-29

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 96/00056

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest



The additional search fees were accompanied by the applicant's protest.



No protest accompanied the payment of additional search fees.

The problem claimed relates to  $\alpha$ -amylase variants with increased thermostability, increased stability towards oxidation and/or reduced  $\text{Ca}^{2+}$  dependency. The solution to this problem is to make an amendment in a parent  $\alpha$ -amylases having the amino acid sequences shown in SEQ ID No 1, SEQ ID No 2, SEQ ID No 3 and SEQ ID No 7.

"A search for a special technical feature" as mentioned in PCT Rule 13.2 among the independent claims did not reveal a unifying, novel technical feature. The fact that all of the three different types of  $\alpha$ -amylase variants come from the same 4 parent  $\alpha$ -amylases (SEQ ID No 1, SEQ ID No 2, SEQ ID No 3 and SEQ ID No 7) does not form a general inventive concept. Accordingly, the following inventions were found:

- I Claims 2-6, part of claim 1 and part of claims 12-29 directed to a variant of a parent  $\alpha$ -amylase which exhibits increased stability towards oxidation
- II Claims 7-10, part of claim 1 and part of claims 12-29 directed to a variant of a parent  $\alpha$ -amylase which exhibits increased thermostability
- III Claim 11, part of claim 1 and part of claims 12-29 directed to a variant of a parent  $\alpha$ -amylase which exhibits decreased  $\text{Ca}^{2+}$  dependency

The search has been restricted to the first invention.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

01/04/96

International application No.

PCT/DK 96/00056

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A1- 9510603	20/04/95	NONE	
WO-A1- 9521247	10/08/95	NONE	
WO-A1- 9526397	05/10/95	NONE	
WO-A1- 9402597	03/02/94	NONE	
WO-A1- 9116423	31/10/91	EP-A, A- 0528864 US-A- 5208158	03/03/93 04/05/93
WO-A1- 9418314	18/08/94	NONE	
WO-A2- 9100353	10/01/91	AU-B- 638263 AU-A- 5953890 CA-A- 2030554 CN-A- 1050220 EP-A, A, A 0410498 JP-T- 4500756 US-A- 5364782	24/06/93 17/01/91 30/12/90 27/03/91 30/01/91 13/02/92 15/11/94
FR-A1- 2676456	20/11/92	NONE	
FR-A1- 2665178	31/01/92	NONE	
WO-A2- 9535382	28/12/95	NONE	
US-A- 4600693	15/07/86	NONE	
WO-A1- 8700202	15/01/87	EP-A, A, B 0229161 JP-T- 63500215	22/07/87 28/01/88

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**